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Abstract 
Three mixed-ligand metal-metal bonded complexes containing one unsymmetrical 
anionic bridging ligand were successfully synthesized and characterized as to their 
electrochemical and spectroscopic properties. The investigated mono-substituted 
diruthenium complexes have the general formula, Ru2(OAc)3(L)Cl, where OAc = 
acetate anion and L = anilinopyridinate bridging ligand (ap, 2-Meap, 2-Fap). UV/Visible 
spectroscopy studies reveal that the investigated diruthenium complexes exist in the 
forms Ru2(OAc)3(L)Cl and [Ru2(OAc)3(L)]+ in solution. The two forms are observed as 
a split band in the 500 – 700 nm visible region. A collapse of one band is seen upon 
reaction of the complexes with excess halide (Cl-, Br-) indicating an equilibrium shift 
towards the neutral species in solution, whereas a reaction with AgBF4 precipitates the 
chloride as the AgCl salt, leaving only the cationic species in solution. Electrochemical 
characterization of the mixed-ligand diruthenium complexes conclusively reveals a 
stable Ru25+ oxidation state in all three complexes. Upon an applied potential in a non-
coordinating solvent, each complex undergoes a reversible one-electron oxidation and 
reduction process accessing the Ru26+, and Ru24+ oxidation states respectively. The 
treatment of human breast adenocarcinoma MCF-7 cells with these water-soluble 
complexes results in a less than 50 % cell survival. This demonstrates significance of 
solubility in the development of metallodrugs for cancer treatment.   
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Chapter 1 
Review of metal compounds; potential applications as anti-cancer 
agents 
1.1 Introduction 
The search for an organometallic compound with improved biological properties 
gained momentum since the discovery  of a precious metal, platinum in the 1960s.1  
Included in the search were metals such as gold (Au), which was used in the treatment 
of cancer, as well as rheumatoid arthritis; silver (Ag) useful as anti-microbial agents.1At 
the time, the platinum metal was very rare and therefore was believed to benefit health 
related issues.2 
With time and in-depth research on the metal, medical properties of platinum 
compounds were then linked to specific biological properties.3 The explanation of the 
mode of action of the platinum metal is however complex, therefore, the exact route 
activity for most drugs is still unknown.2 Scientists have now resorted to solving the 
mechanism of action of these drugs step by step and the results are then used to 
design an anti-cancer drug with improved potency and little to no side effects.3 
The most studied and well knownorganometallic complexes consist of metals that 
belong to the platinum group metals, as they displayed anti-cancer activities.4 The 
unpremeditated discovery of anti-cancer properties of cisplatin paved a way for 
research into other platinum complexes to be used in cancer therapy.4 Platinum drugs 
are still used in clinics and more drugs are still undergoing clinical trials not just to treat 
cancer but other diseases such as parasitic and bacterial infections.5 Although some 
of the compounds have not been clinically approved, uses of other metals of the 
platinum, gold and silver group in medicine include; anti-cancer, dental alloys, 
microbial, anti-HIV, bronchial asthma and rheumatoidarthritis.5 
Applications of metal drugs as anti-cancer agents stems from 1965, when Rosenberg 
accidentally discovered the activity of a platinum compound cisplatin, [(cis-
Pt(NH3)2Cl2].6 Since then, metal based compounds became an area of research due 
to their material, catalysis and optical properties which led to applications in medicinal 
fields.7In medicine, interest in metal compounds arises from the remarkable 
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effectiveness of the platinum-based compound cisplatin, [(cis-Pt(NH3)2Cl2] and its 
analogues for the treatment of testicular, ovarian, head and lung cancer, of which the 
cure rate was found to be greater than 90% in testicular cancer cases.8 Cancer 
remains chronic because in spite of current medical interventions, no cure has been 
found and some anti-cancer drugs are not effective over a wide range of cancers.9,10 
In 2012, the globocan project of the world health organization (WHO) reported that 
cancer had resulted in about 8.8 million deaths world-wide.11Furthermore, it is 
amongst the top twenty causes of deaths in South Africa claiming about 14 % of the 
population.11 
Although cisplatin is effective over a wide range of cancers, it is limited by its toxicity, 
poor solubility and the fact that it targets normal cells over those of cancerous cells.12 
In addition; it was found that cancer had become resistant towards the cisplatin drug; 
this was due to the changes in cellular uptake, efflux and increased detoxification of 
the drug.13 
Metals such as arsenic, cadmium and lead were also found to be highly reactive and 
used as therapeutic agents; however, they were limited by their high toxicity.13,14,15 
Arsenic trioxide (ATO) (figure1.1) is the only non-platinum compound that has been 
approved for clinical use thus far.13 This drug was used before and was re-discovered 
in 1997 when there were reports on complete remissions in Acute Promyelocytic 
leukaemia (APL) patients.14,15 The compound as an anti-tumour drug was approved in 
2000 by the FDA for the treatment of APL. Evaluation of ATO for the therapy of other 
cancers is still taking place.16 
 
 
 
Figure 1.1: Structure of Arsenic trioxide (ATO).13 
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The arsenic trioxide compound works on particular proteins within the cell which 
speeds up the death of leukaemia cells at the same time encouraging normal blood 
cells to develop properly.17 This drug is administered through a drip into the arm and 
the drip lasts for about 1-2 hours. Its mode of action is not fully understood but 
speculations are that it causes cell death of leukaemia cells via DNA fragmentation.18 
Furthermore, it damages the fusion promyelocytic leukaemia (PML).17,18 The function 
of arsenic trioxide is therefore to treat acute promyelocytic leukaemia by stopping the 
growth of cancer cells.18 
Side effects of the compound include QT prolongation, meaning that the heart muscles 
take longer to recharge between beats due to an electrical disturbance and this is 
capable of causing serious heart rhythm problems.17 This compound may also result 
in unusual bruising or bleeding, decreased urination, hives and seizures, swelling of 
the arms and headaches.17 
This has compelled the development of new effective metal compounds as anti-cancer 
agents. Various non-platinum antitumor agents such as dinuclear carboxylate species 
of rhodium (Rh),19 rhenium (Ir)20 and ruthenium (Ru)21 have been reported over the 
past few years. Rh(III) and Ir(III) complexes containing bidentate aromatic ligands 
have shown that high cytotoxicity in cancer cells can be achieved by selection of a 
prudent ligand.22 The exact mechanism of how the compound targets the cells is not 
known, however, these compounds have been reported to induce cell death through 
an intrinsic mitochondrial pathway.23 
In spite of the fact that the octahedral rhodium and iridium complexes show promise 
as anti-cancer agents, the cytotoxicity of these complexes strongly depend on the type 
of ligand coordinated to the dimetal unit.24 The rate of ligand exchange, accessible 
oxidation states, as well as the ability of ruthenium to mimic iron during binding to 
certain biological molecules are what makes ruthenium useful in drug design.25 
Ruthenium containing complexes that offer reduced toxicity is an area of research that 
is gaining momentum towards identifying suitable drugs that are highly soluble, and 
selectively target cancerous cells over normal cells.19,21 Investigations of anti-cancer 
agents have suggested DNA as a primary intracellular target.13 
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Recent findings claim that ruthenium complexes have displayed anti-cancer properties 
in-vivo such that by simply changing the ligand environment around the dimetal core, 
stimulates mechanism of action that does not result in the damage of normal cells.26 
This chapter is a review of previously investigated metallodrugs and their suggested 
mode of action. Ruthenium complexes undergoing clinical trials will be discussed as 
well as dinuclear ruthenium complexes, together with the introduction of 
anilinopyridinate ligands which were used as substituents in the synthesis of mixed-
ligand diruthenium complexes.  
1.2 Platinum-based metallodrugs 
Platinum is an inert transition metal in Group 10 of the periodic table and is considered 
a precious metal because it is rare and desirable.27 The neighbours of this metal 
include iridium, palladium, ruthenium, osmium and rhodium, hence they are 
sometimes called platinum group metals.27 The five metals are best known for their 
catalytic properties and are used to make compounds that end up as drugs, synthetic 
fibers and used in pharmaceuticals.27 
The metallodrugs research was incited by the discovery of anti-cancer properties of 
platinum by Rosenberg, where running the electric current using the platinum 
electrode killed E-coli.28,29 This observation sparked interest in the precious metal 
platinum and led to the synthesis and testing of a series of platinum based compounds 
such as, [(cis-Pt(NH3)2Cl2], known as cisplatin.29 In all the effort throughout the years, 
there has only been 2 world-wide drug approvals for platinum containing drugs which 
are carboplatin, discovered in 1992 and oxaliplatin, discovered in 2002 (figure 1.2).7 
The approved drugs are both direct analogues of cisplatin. 
Pt(II) is a soft metal ion with a strong affinity for soft ligands such as sulfur.30 Once 
cisplatin is administered, the Pt metal gets removed by sulphur containing ligands such 
as (N-acetyl-L-cysteine)glutathione in the system.30 The suggested mode of action of 
cisplatin (figure 1.2 (1)) is that the chloride ligands get hydrolyzed within the cell and 
this generates a bis-aqua species which then irreversibly binds to DNA.8 
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This action inhibits cell replication resulting in controlled cell death, known as 
apoptosis.8 This compound forms inter and intra strand cross links in the DNA which 
in turn prevents DNA replication and transcription, resulting in cell death.31 
Carboplatin differs from cisplatin as it has a bidentate dicarboxylate instead of two 
chloride ligands which exchange with water molecules in-vitro.31 Carboplatin (figure 
1.2(2)) forms the same products as cisplatin in-vitro, even though it was found to  
exhibit lower and slower reaction DNA binding kinetics.31 Oxaliplatin contains 
bidentate ligands, 1,2-diaminocyclohexane in place of the monodentate aniline ligands 
(figure 1.2 (3)).  
 
Figure 1.2: Chemical structures of Cisplatin (1), Carboplatin (2) and Oxaliplatin (3).7 
The side effects of previously investigated anti-cancer drugs and their unknown 
mechanism of action necessitated the search for improved compounds as anti-cancer 
drugs. Members of the platinum group such as ruthenium, rhodium, palladium, 
osmium and iridium have since been investigated. 
 
Platinum-based compounds are still regarded as the most successful chemotherapy 
agents, with an estimated 70 % of patients receiving the compound as part of the 
treatment.32 While cisplatin is effective over a wide range of cancers, the clinical 
application of cisplatin is hampered by its high toxicity and poor solubility in-vivo.33 
Moreover; it was impeded by side effects such as nerve damage, hair loss and 
nausea.7 Platinum–based drugs used in chemotherapy are now known to also target 
normal cells resulting in normal cell damage.32,33 These shortcomings along with other 
disadvantages of the use of cisplatin has driven research towards different strategies 
in the development of new metal based anti-cancer agents with different modes of 
action.34 
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1.3 Ruthenium based metallodrugs 
During the evaluation of ruthenium complexes as anti-cancer drugs, it was discovered 
that they exhibit similar ligand exchange kinetics as Pt(II) complexes.34 The interaction 
of the metal drug with macromolecules such as proteins and H2O is an important 
factor.34 This is because it induces  the desired therapeutic properties of the complex.34 
The rate of ligand exchange of ruthenium compounds depends on the concentration 
of exchanging ligands in the media.35 
Ruthenium metal, amongst the platinum group, has oxidation states Ru(II), Ru(III) and 
Ru(IV) which are  all accessible under physiological conditions.36 In addition, there is 
a low energy barrier between the accessible oxidation states making it easier to 
interconvert between the oxidation states when inside the cell.36 Ruthenium also 
displays a relatively slow ligand exchange rate between 10-4/10-2 S-1 in water (figure 
1.3).36 The kinetics of ruthenium is on the timescale of cellular reproduction, this 
means that when ruthenium binds to a bio-molecule in the cell, there is a high chance 
that it remains bound for the remainder of the cells lifetime.36 
 
Figure 1.3: The ligand exchange rates of selected transition metals.36 
 
The molecular geometry of ruthenium metal complexes have an octahedral geometry 
and Ru(III) complexes are more biologically inert than Ru(II) and Ru(IV) complexes.35 
Furthermore, the redox potential of ruthenium complexes can be changed by varying 
ligands.35 Once the ruthenium compound is administered, ascorbates and other single 
electron transfer proteins can reduce Ru(III) and Ru(IV) or oxidise Ru(IV) by 
cytochrome oxidases (figure 1.4).1 These are important properties of ruthenium 
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compounds because effective and improved drugs in clinic can be designed by 
exploiting the redox potentials of the ruthenium complexes.  
 
Figure 1.4: The oxidation state modifications of ruthenium in cancerous and healthy 
cells.1 
Ruthenium compounds promise to exhibit less to no toxicity properties and this can be 
attributed to its ability to mimic iron in binding to biomolecules such as serum 
transferrin and albumin.37 Cancerous cells have a greater requirement for iron; 
therefore, they increase the number of transferrin receptors in the cell surface, in that 
way segregating the circulating metal-loaded transferrins as shown in figure 1.5.37 
Figure 1.5 shows a schematic representation of selective uptake of transferrin by 
cancer cells and because the drug is designed to target cancerous cells, its toxicity 
gets reduced as only a small amount of it reaches healthy cells.1,37 This is due to the 
fact that metal-loaded transferrin gets delivered according to the number of transferrin 
receptors on their surfaces.1 
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Figure 1.5: description of the selective uptake by the cancer cells.1 
Ruthenium based-compounds have been developed and tested against cancer cell 
lines and were found to have fewer side effects compared to cisplatin.21,33 In addition, 
their properties such as activation by reaction and the great coordination to cellular 
ligands make them to be well suited towards pharmaceutical applications.38,39 The 
speculation of the possible binding mode of DNA to ruthenium is that the molecule 
gets inserted between the DNA base pairs.40 
The application of ruthenium compounds as anti-cancer agents requires a precise 
understanding of the agents` mechanism of interaction with the molecule that is 
targeted, double helix DNA.41 There are two possible ways that DNA binding agents 
can interact with the host molecule and this is through a groove-binding fashion, which 
is stabilized by a mixture of hydrophobic, electrostatic and hydrogen-bonding 
interaction as shown in figure 1.6.41 Another mode of binding is through an intercalative 
association whereby a planar, hetero aromatic moiety slides between the DNA based 
pairs.40 This type of binding is known as intercalation and applies to ruthenium 
compounds that contain planar fused aromatic ligands, an example of intercalation 
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association is illustrated in figure1.6(a).40 The insertion results in the π-electron 
overlap of the aromatic ligands of the compounds with the base pair. 
 
 
(a)                           (b)                                    (c) 
Figure 1.6: Illustration of modes of binding, intercalation (a), groove binding (b) and 
threading binding (c).  
Studies show that Interaction of ruthenium with DNA can be monitored by changes in 
plasmid electrophoretic mobility42, such that alteration of the mobility would imply 
disturbance of the DNA by a ruthenium compound.42 Menendez et al successfully 
synthesized a series of mono-ruthenium complexes containing planar aromatic 
bridging ligands.42 From the in-vitro experiment, it was found that mono-ruthenium 
compounds showed great solubility in aqueous media and interacted with plasmid 
DNA for the different enantiomers.42 
Ruthenium containing complexes show promise in anti-cancer activity in-vivo and in-
vitro.42 So far, there are two ruthenium compounds which have entered clinical 
evaluation and that is, NAMI-A(imidazolium trans-(tetrachloro(dimethyl 
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sulfoxide)(imidazole) ruthenate (III)43 and KP1019 (indazolium trans-
(tetrachlorobis(1H-indazole)ruthenate (III)44 (figure 1.7). These compounds contain 
ligands that can be hydrolysed and this leads to a chloride-water substitution 
reaction.45 
Due to hydrolysis, the actual active molecules that reach cancer cells become different 
from the molecular structures shown in figure 1.7.46 The investigated compounds, 4 
and 5 appeared to be quite similar structurally, both having the III oxidation state with 
chloride, heterocyclic ligands and a heterocyclic counter ion, however, have shown 
great display of different types of anti-cancer activity.46 
KP1019 was found to be active against the main tumour mass that forms first in a 
patient, known as primary cancer. It was reported that this compound is highly active 
against colon cancer.19 4 is active against the metastases that forms after cells from 
the primary tumour have moved to a different organ via the blood stream, and these 
are secondary tumour cells.19 The two complexes are promising as anti-cancer agents 
as they have shown a high tolerance in clinical phase trials with low side effects more 
especially 5.43,44 
4 and 5 are both mono-ruthenium compounds with the Ru(III) oxidation state and there 
is still research going on for the mono-ruthenium complexes.44 Following the Ru(III) 
compounds are the Ru(II) organometallic compounds with arene ligands which are still 
undergoing pre-clinical evaluation.47 Ruthenium based compounds have shown highly 
promising anti-cancer activity cells both in animals and humans.45 
Although some mono-ruthenium compounds exhibit anti-cancer properties, little   
knowledge is known about their exact mode of action,48 therefore, this has urged 
chemists to synthesize and test a series of novel complexes in order to elucidate the 
modes of action. What is known about the mode of action of these compounds is that 
it targets the DNA.47 In addition, their induced damage as well as their pharmacological 
and chemical behaviour was found to be different from those of platinum-based 
drugs.47 This  suggests that there could be additional cellular targetsin-vitro.47 
11 
 
 
Figure 1.7: Chemical structures of NAMI-A (4) and KP1019 (5) 
1.4 Dinuclear ruthenium complexes 
Metal-metal bonded complexes herein referred to as the dinuclear ruthenium 
complexes, have ignited growing interest since the discovery of the first dimetal 
complex, Re2Cl82-.49 This complex was unusual in that it had multiple bonds between 
metals with no supporting equatorial bridging ligands. Following the discovery of 
Re2Cl82-, several other multiple bonded metal-metal complexes of ruthenium, rhenium, 
rhodium, molybdenum, platinum, iron, iridium, palladium and vanadium were reported 
in the literature.13The multiple metal-metal bonds are typically supported by O, 
O’(acetates), N, O’ (hydroxypyridinates and oxopyridinates) or N, N’ (pyridinates and 
formamidinates) equatorial bridging ligands. Examples of some of these ligands are 
illustrated in figure 1.8.  
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Figure 1.8: Examples of symmetrical or unsymmetrical ionic bridging ligands with 
varied donor groups.  
In 1966, the structure of Ru2(OAc)4Cl, (OAc = an acetate bridging anion) was first 
reported by Stephenson and Wilkinson.50 Subsequent work led to the characterization 
of the diruthenium tetracarboxylate having a paddle-wheel geometry as illustrated in 
figure 1.8.50 Cotton and Co-workers provided evidence that the Ru-Ru bond is strong 
with a bond order of 2.5 and a short distance of 2.281(4) Å.51 
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A detailed computational analysis of the paddlewheel complexes with a Ru25+dimetal 
unit led to a proposed electronic configuration of (δ)2(π)4(δ)2(δ*π*)3.40 
 
Figure 1.9: The structural representation of a diruthenium tetracarboxylate, 
Ru2(OAc)4Cl.40 
Their unique physical and electronic properties are liable for the expansion of 
diruthenium complexes and analogous compounds.52,53 Nowadays, the most 
investigated metal-metal complexes are mixed with nitrogen containing bridging 
ligands and are formulated in their neutral form as Ru2(L)4Cl or Ru2(OAc)4-x(L)xCl, 
where L is a symmetrical or unsymmetrical anionic bridging ligand (Chart 1.1). The 
deviation from diruthenium tetracarboxylates to mixed-ligand diruthenium complexes, 
is largely due to the fact that the order of the molecular orbitals of the metal centre 
varies with changes in the type of the equatorial ligands.54 
The diruthenium complex has two oxidation states, one with the Ru(III) and the other 
with Ru(II) oxidation state. However, these atoms are chemically equivalent and are 
therefore represented as Ru25+which is the overall oxidation state.51 A diagram of the 
Ru25+ dimetal core with 11 electrons placed in a molecular orbital is shown below 
(figure 1.9). There are three unpaired electrons and a very small energy gap between 
the δ* and π* orbital thus favouring the high spin 3/2 configuration. 
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Figure 1.10: Diagram of the molecular orbitals of a Ru25+dimetal core.51 
Mixed-valent tetracarboxylate diruthenium complexes were found to be only 
moderately active against P388 lymphocytic leukaemia cell lines.19 There was 
therefore a need to exploit this class of complexes by introducing ligands that greatly 
enhances their solubility. This was done by introducing nitrogen containing ligands 
towards the synthesis of a series of mixed-ligand diruthenium complexes.  
The anionic bridging ligands introduced were found to have an impact on the dimetal 
core of the complex,  in such a way that the metal centre varies with the changes in 
the type of the axial and equatorial ligands.54 Varying the ligand types were found to 
also affect the redox potential, electronic configuration and the chemical reactivity of 
the diruthenium complexes in their different oxidations states.54 The importance of 
pyridine ligands over acetate bridging ligands is that the dimetal unit of the compound 
can be tuned via ligand design. 
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1.5 Mixed-ligand diruthenium complexes. 
Previously investigated diruthenium complexes such as Ru2(OAc)4Cl were found to be 
moderately soluble in aqueous media.45 In anti-cancer studies, the solubility of a 
compound is an important factor as it has an impact on the biological activity.55 It was 
therefore important to modify mixed-ligand diruthenium complexes and make them 
suitable for application in medicinal field.  
Diruthenium complexes having the general formula, [Ru2L4]n+, where L is defined as 
an unsymmetrical bridging ligand and n = 0 or 1, have four possible isomer types, 
namely, (4,0), (3,1), (2,2)-cis and (2,2)-trans (chapter 2, chart 2.1).56 However, most 
diruthenium complexes have been isolated as (4,0) or (3,1). The significance of 
pyridine and anilinopyridine based ligands is that they have been isolated as discrete 
molecules in the solid state.57This is a different behaviour to the complexes with N,O’ 
and O,O’ ligands that form polymeric structures.58 
Kadish et al 59 synthesized a series of diruthenium complexes containing the ap-type 
bridging ligands according to eqn 1. The synthetic procedure involves the melt reaction 
of a substituted anilinopyridinate ligand with a tetracarboxylate diruthenium complex 
which could proceed for 4 - 15 hours depending on the type of the bridging ligand.  
Ru2(OAc)4Cl + 4HL             Ru2(L)4Cl + 4(OAc)   (1) 
The reaction of the compound, Ru2(OAc)4Cl with excess anilinopyridinate bridging 
ligand results in a stepwise metathesis displacement of the acetate ligand by the 
incoming ligand (scheme 1.1). The extent of the replacement of the acetate can be 
altered by varying the reaction conditions such as temperature, reaction time and 
choice of solvents.60For example, in the case of the fluorinated compound, in literature 
a series of diruthenium complexes with the general formula, Ru2(OAc)x(Fap)4-xCl (x = 
0-4) were isolated.60 
The synthesis of Ru2(Fap)4Cl and three lesser substituted mixed-ligand Ru25+ were 
synthesized from a single reaction of Ru2(OAc)4Cl and H(2-Fap) in refluxing methanol. 
The yields for a 6 hour reaction under the conditions stated were 30.2, 20.1, 24.2 and 
4.8 % obtained for the complexes Ru2(Fap)4Cl, Ru2(OAc)(Fap)3Cl, Ru2(OAc)2(Fap)2Cl 
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and Ru2(OAc)3(Fap)Cl, respectively.60 The complexes have the Ru25+ diruthenium 
core and are shown in scheme 1.1 (1-3). 
Furthermore, an isolation of Ru2(OAc)(2,4,6-Me3ap)3Cl has been isolated from the 
reaction of Ru2(L)4Cl with H(2,4,6-Me3ap).61 The findings proved that these types of 
metal-metal bonded ruthenium complexes lead to a stepwise metathesis displacement 
reactions. Whereby, it is possible not to only isolate a fully substituted diruthenium 
complex, Ru2(L)4Cl but three more derivatives, Ru2(OAc)2(L)2Cl, Ru2(OAc)(L)3Cl and 
Ru2(OAc)2(L)2Cl can be isolated from a single reaction.  
 
Scheme 1.1: Diagram indicating the structures of the complexes in the 
Ru2(OAc)x(Fap)4-xCl, (x = 0-3) series.60 
Kadish and Bear have reported comprehensive studies on the asymmetric 2-
anilinopyridinate, Ru2(ap)4Cl and 2-fluoroanilinopyridinate, Ru2(Fap)4Cl diruthenium 
complexes.57 This series of complexes have been crystallized in either the (3,1) and 
(4,0) isomer types. The existence of (2,2)-cis and (2,2)-trans isomeric forms were 
postulated but compounds have not yet been isolated. The formation of the (4,0) and 
(3,1) isomer types were attributed to either electronic, steric effects or a combination 
of the factors.57 
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Diruthenium complexes [Ru2(L)4Cl] studied previously, with L being anilinopyridinate 
(ap), fluoroanilinopyridinate (2-Fap), and F5ap were shown to have different isomeric 
distributions, this indicates that the steric and electronic effects of the anilinopyridinate 
ligands play a role in the  preferred conformation of the complexes.56 
Spectroscopic, electrochemical and structural characteristics of mixed ligand 
diruthenium complexes were analyzed.59 From the findings, it was concluded that the 
complexes with 2-Meap and 5-F2ap as bridging ligands only exist in a (4,0) isomeric 
form whereas both (3,1) and (4,0) was obtained for the Ru2(2,4,6-F3ap)4Cl compound 
(table 1.1). Previous studies have reported on the effect bridging anilinopyridinate 
anions with electron donating/withdrawing group at the ortho, meta or para positions 
of the aniline ring have on the dimetal unit.59 These compounds have been analyzed 
as to their spectroscopic, electrochemical and structural properties.59 
According to the study by Kadish et al 59, the number or nature of the ligand affects 
the geometric isomer of a complex. Moreover, out of the compounds they have 
studied, the findings are that only those with two substituents at the ortho positions of 
the phenyl ring exist in more than one isomer.59 Below is a table with isomeric 
distributions showing the impact an anilinopyridinate ligand coordinated to the dimetal 
core has on the isomer type of a complex.62,63 
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Table 1.1:  UV/Visible spectral data of the (4,0) and (3,1) isomers of Ru2(L)4Cl, 
where L is 2-CH3ap, ap, 2-Fap, 2,5-F2ap, 2,4,6-F3ap, 2,6-F2ap, and F5ap, in CH2Cl2 
containing 0.2 M TBAP 
        λmax nm (ε x 10 -3, M-1 cm-1) 
Oxidation 
state 
ligand Band I Band II Band III Band IV 
 (4,0) Isomer 
Ru26+ CH3ap (1) 443(6.9) 530(6.5)  990(15.9) 
 2,4,6-F3ap(2) 432(2.9) 522(3.9) 842(sh) 1033(3.8) 
 2,5-F2ap (5) 413(5.5) 504(5.5)  975(11.2) 
 F5ap  520(6.4) 900(sh) > 1050 
Ru25+ CH3ap 424(4.3) 461(4.7)  764(7.3) 
 ap 421(5.8) 452(5.7)  778(7.0) 
 2,4,6-F3ap  412(2.2) 476(2.6) 615(0.7) 895(2.7) 
 2,5-F2ap 422(4.8) 466(5.3)  774(5.8) 
 F5ap  482(5.8) 598(1.1) 910(5.0) 
Ru24+ CH3ap  534(3.6)   
 2,4,6-F3ap  507(1.4)   
 2,5-F2ap  515(4.1)   
 F5ap  518(3.2)   
 (3,1) Isomer 
Ru26+ 2-Fap 431(4.1) 494(3.9)  960(5.2) 
 2,4,6-F3ap 487(5.7) 670(4.4)  965(9.5) 
Ru25+ 2-Fap 428(3.6) 463(3.6)  750(3.9) 
 2,6-F2ap 422(4.2) 475(4.0)  788(3.9) 
 2,4,6-F3ap 418(4.5) 476(4.7)  777(4.5) 
Ru24+ 2-Fap  482(sh)   
 2,4,6-F3ap  476(sh)   
 F5ap  486(sh)   
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It has been reported that the solubility of diruthenium complexes can be improved by 
abstracting the axial chloride ligand from the dimetal core, by reacting the compound 
with silver salts.64 The reaction should leave the axial position of the dimetal unit 
available for coordination.  To achieve a water soluble compound, halide abstraction 
experiments have been performed on diruthenium compounds such as Ru2(OAc)4Cl 
with salts like AgClO4 (silver perchloroate), AgTFA (silver trifluoroacetate), and AgNO3 
(silver nitrate).64 
Moderate donor solvents such as acetone, methanol, ethanol and tetrahydrofuran 
involving the [Ru2(OAc)4+] core have been used. In this instance, a 50/50 
methanol/water was found to be the most common mixture for axial de-chlorination.65 
Dunlap et al 65 synthesized a series of charged diruthenium complexes using different 
salts. The reaction of interest extracted from the literature was that of Ru2(OAc)4Cl 
with AgNO3, the starting materials were dissolved in de-ionized water which was then 
heated for 4 hours. The same methodology was used for axial de-chlorination using 
salts like AgBF4, and AgTFA.  
The main goal of these reactions was to afford de-chlorination and the precipitation of 
AgCl. From their study, it would seem that most of the investigated species can be 
produced from aqueous solutions.65 Alcohol aqueous mixtures were of preference to 
produce the desired water soluble complexes and this was due to the fact that the 
reactions resulted in lower reaction times, lower temperature as well as higher yields.65 
It was however emphasized that ions that could bind to the [Ru2(OAc)4]+core had 
restrictions. AgNO3 is a good silver salt for de-chlorination because it was found to be 
one of the weakest donor anions.65 
The driving force of their study was to invigorate further investigations into the aqueous 
chemistry of [Ru2(OAc)4]+ as it is one of the significant compounds in  the journey of 
understanding cytotoxic, kinetic and catalytic behaviour of the diruthenium  
complexes.45 For anti-cancer studies, it was important that aqueous solvents are used 
as the cytotoxicity examination of the ruthenium compounds are done in aqueous 
media.55 
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1.6 Aims and objectives 
The aim of this research was to synthesize and characterize mono-substituted mixed 
ligand diruthenium complexes. The design will be such that the complexes are more 
soluble in aqueous and most organic solvents. The target complexes will be such that 
the electric properties of the unsymmetrical bridging ligands affect the liability of the 
axial ligand. In this manner, the solubility properties of the complexes can be tuned. 
Substitution of the equatorial ligand with electron donating and withdrawing substituent 
allows for the accessibility of different oxidation states of the dimetal core. The desired 
complexes were exclusively isolated by optimizing reaction conditions such as reflux 
time, temperature and solvent type. We also attempted to abstract the chloride ion 
bound to the dimetal core to give a soluble diruthenium complex. The synthesized 
complexes were then evaluated as potential anti-cancer agents. 
To achieve these aims, the project was divided as follows:  
• The synthesis and characterization of unsymmetrical anilinopyridinate ligands 
i.e anilinopyridinate, (Hap), 2-methylanilinopyridine, H(2-Meap) and 
fluoroanilinopyridine, H(2-Fap).  
• The synthesis and characterization of a series of mono-substituted mixed-
ligand diruthenium complexes: Ru2(OAc)3(ap)Cl, Ru2(OAc)3(2-Meap)Cl and 
Ru2(OAc)3(2-Fap)Cl. 
• Electrochemical studies of the complexes 
• Cytotoxicity studies of the synthesized diruthenium complexes. 
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Chapter 2 
Synthesis and spectroscopic characterization of mono-substituted 
diruthenium complexes. 
2.1 Introduction 
Metal-metal bonded complexes containing chelating nitrogen ligands continue to be a 
highly researched area following the successful physical characterization of the Ru25+ 
diruthenium complex, Ru2(OAc)4Cl for the first time in 1966.1 Studies show that 
changing the donor atoms of the bridging ligands coordinated to the dimetal core does 
not only affect the structural characteristics of the complexes, but also modifies the 
electronic configuration.2 
Cotton and co-workers showed that the near degeneracy of the π* and δ* orbitals 
(chapter 1, figure 1.10) can be lifted by changing the O, O’ bridging carboxylate to N, 
O’ or N, N’ chelating ligands.3,4 This is because the lowest unoccupied molecular 
orbitals (LUMOs) of pyridines have the right symmetry to interact with the Ru – Ru π* 
highest occupied molecular orbital (HOMO).5 
Owing to the increased basicity of H2NOCCF3 ligand compared to the acetate 
counterpart, the electrochemistry of the complex, Ru2(HNOCCF3)4Cl can be altered 
compared to the Ru2(OAc)4Cl complex.3,4 Nitrogen containing ligands are therefore of 
great importance mainly due to their ability to change the molecular orbital order of the 
dimetal centre. The choice of nitrogen containing bridging ligands is largely due to the 
fact that the anilinopyridinate anions have delocalized π systems which account for 
the stabilization of the Ru (II) – Ru (III) core.5 
The substitution of the acetate ligand by the nitrogen containing ligands proceeds via 
a stepwise metathesis displacement with the mixed-ligand complexes Ru2(OAc)xL4-xCl 
as intermediates. In this chapter, we report the synthesis and characterization of 
mono-substituted mixed-ligand diruthenium complexes having the general formula, 
Ru2(OAc)3(L)Cl, where L is an unsymmetrical bridging anilinopyridinate ligand. In 
literature, the Ru25+ complexes are reported to have four possible isomer types, 
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namely, (4,0), (3,1), (2,2)-trans and (2,2)-cis (figure 2.1) but most diruthenium 
complexes have been isolated as a mixture of (3,1) and (4,0) isomers.6 
Figure 2.1: Possible geometric isomers of mixed-ligand diruthenium complexes 
Unsymmetrical anilinopyridinate bridging ligands having different substituents are 
ligands of interest. This is because they have been shown to be able to stabilize 
different oxidation states of the dimetal centers.5-8 The reactivity of these ligands has 
been studied on metals such as: Cr9, Rh10, Ru5 and Mo11, where tetracarboxylates 
were mostly used as starting materials for the synthesis of anilinopyridinate based 
metal complexes.12 
Coordination with the dimetal centers occurs through the pyridino and anilino nitrogen 
atoms. The bidentate coordination results in a N-C=N three atom bridge. Studies show 
that the substituent bonded to the anilino ring of the investigated ligands affect the 
structural and spectroscopic characteristics of the complex.13,14 Therefore, the effect 
these electron withdrawing or donating substituent have on the dimetal core were 
investigated and reported. The unsymmetrical substituted anilinopyridinate ligands 
investigated are labelled as: Hap (L1), H(2-Meap) (L2) and H(2-Fap) (L3) (figure 2.2).  
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Figure 2.2: Anilinopyridinate ligand systems investigated in this study 
2.2 Results and discussion 
2.2.1 Synthesis and characterization of substituted anilinopyridinate ligands. 
The ligands, anilinopyridine (Hap), 2-methylanilinopyridine (H(2-Meap)) and 2-
fluoroanilinopyridine (H(2-Fap)) ligands were synthesized following a procedure 
reported in literature.10 As shown in Scheme 2.1, 2-bromopyridine and substituted 
aniline were heated at 170 °C under a nitrogen atmosphere for 7 hours. All the ligands 
produced solid crude products.  
The ligands were recrystallized three times in hot hexane to afford white crystals. All 
the ligands showed good solubility in polar solvents such as chloroform, 
dichloromethane, ethyl acetate, diethyl ether and methanol. The ligands were 
characterized by mass spectrometry, 1H and 13C NMR and FTIR spectroscopy as well 
as elemental analysis.  
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Scheme 2.1: General synthetic route of the anilinopyridinate ligands 
2.2.1.1 Nuclear magnetic resonance of anilinopyridinate ligands. 
All the ligands were characterized with proton and carbon NMR spectroscopy obtained 
in CDCl3. In this section, a representative characterization of L2 by NMR is discussed. 
The most characteristic signal, confirming the formation of the ligand from 2-
bromopyridine and methylaniline is the N-H proton, the broad singlet observed at 6.30 
ppm (figure 2.3). The 1H NMR spectrum shows a singlet signal of the methyl group at 
2.23 ppm. The peaks ranging from 6.5 – 8.10 ppm are assigned to the aromatic 
protons (Ha-Hh). The doublet signal (Hh) at 8.10 ppm is more de-shielded as compared 
to the other aromatic protons because it is only two bonds away from the 
electronegative nitrogen in the pyridino ring.  
Hg is bonded to the pyridino ring whereas Hb to the anilino ring and they are both para 
to the N-H proton. Their signal is characterized by a doublet of doublet for Hg and a 
doublet of doublet Hb appearing as a multiplet at 6.60 ppm. Hg is slightly de-shielded 
because it is in the ring that contains Nitrogen. Hc and Hf, both at meta positions to the 
N-H group, both have doublet of doublets signals assigned to the multiplet peak at 
7.41 ppm with Hf slightly de-shielded (7.43ppm) and Hf at 7.40 ppm.  
Hd, in the pyridino ring ortho to N-H as well as He in the anilino ring which is also ortho 
to N-H are each characterized by a doublet signal and their signal appears at 7.15 
ppm as a doublet of doublet. The doublet signal at 7.05 ppm is assigned to the Ha 
proton. Similar results with different multiplicities depending on the type of substituent 
were obtained for the other investigated ligands. The broad N-H peak tends to shift 
based on the nature of the substituent on the anilino ring. The N-H peak becomes de-
shielded when there is an electron withdrawing substituent and shielded when the 
substituent is electron donating. For instance, L2 has a N-H signal at 6.30 ppm 
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whereas L3 has a N-H peak more de-shielded at 6.60 ppm. The discrepancy in the 
chemical shift of the broad peaks (N-H) is because L3 contains an electron 
withdrawing substituent (F) on the anilino ring ortho to N-H.  This substituent 
decreases the electron density around the N-H region resulting in an increased 
chemical shift. L2 contains an electron donating substituent (CH3) on the anilino ring; 
this group increases the electron density around the N-H region resulting in a more 
up-field broad peak at 6.30 ppm as compared to that of L2.  
The L1 ligand has a broad peak (N-H) appearing at 6.50 ppm, more de-shielded than 
the N-H peak of the L2 ligand because CH3 is a better electron donating group. L1 
contains aromatic protons, conforming the formation of the desired ligand.  
 
 
Figure 2.3:1H NMR spectrum of H(2-Meap) in CDCl3 
The corresponding 13C NMR signal of L2 occurring at 18.00 ppm is assigned to the 
single carbon bond (C-C) of the methyl group bonded to the anilino ring of the ligand. 
The chemical shift at 107.50 ppm is assigned to the single C-N bond connecting the 
two rings; this further confirmed the formation of the ligand. The chemical shift between 
the ranges of 114 – 150 ppm corresponds to the aromatic carbons of the ligand. The 
more de-shielded signal occurring at 155.50 ppm is assigned to the C=N functional 
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group of the pyridino ring. All the other investigated ligands, L1 & L3 exhibited similar 
13C NMR signals with slight shifts depending on the type of substituent.  
 
Figure 2.4:13C NMR spectrum of H(2-Meap) in CDCl3 
The investigated ligands exhibit a broad N-H signal which indicates the formation of 
the ligand of interest from 2-bromopyridine and substituted aniline. Moreover, aromatic 
protons of both the anilino and pyridino ring were observed on the spectrum. The 
change in chemical shift of the N-H signal upon moving from an electron donating to 
an electron withdrawing substituent indicates that the nature and positioning of the 
substituent influences the electron density of the N-H region.    
2.2.1.2 Characterization of substituted anilinopyridinate ligands with FTIR. 
A (N-H) vibration stretch was expected after the formation of L2 from 2-bromo-
pyridine and 2-methylaniline. This was indeed observed with a stretching frequency of 
3155 cm-1 (figure 2.5).  The vibrational stretch appearing at 2941 cm-1 was assigned 
to the (C-H) stretch. The positioning and intensity of the C-H stretch is related to the 
nature of the other substituents on the ring, in this case, the stretch is affected by the 
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methyl group at the ortho position of the ligand. The intense stretch at 1527 cm-1 is 
attributed to the (C=N) stretch and the 1425 cm-1 frequency assigned to (C-C).  
All the investigated ligands have the same functional groups, C=N, C-H, C-C and N-H 
from the anilinopyridinate rings except that the stretches differ based on the type of 
substituent. For example, H(2-Fap) has a shorter (N-H) vibration stretch compared 
to Hap, this is due to the fact that H(2-Fap) contains an electron withdrawing 
substituent on the ortho position of the anilino ring. This substituent decreases the 
electron density of the N-H region resulting in a less intense stretch.  
In the case of a methyl containing ligand, H(2-meap) has a longer (N-H) vibration 
stretch as compared to H(2-Fap). This this observation was attributed to the fact that 
the ligand contains an electron donating methyl group which increases the electron 
density of the N-H group resulting in a longer stretching frequency.  
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Figure 2.5: FTIR spectrum of H(2-Meap) 
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2.2.1.3 Mass spectrometry and elemental analysis of anilinopyridinate ligands. 
A representative mass spectrum of ligand L2 is shown in figure 2.6. The formation of 
the ligand was indicated by a sharp peak on the mass spectrum. The calculated molar 
mass (184.24 g.mol-1) is consistent with that observed on the mass spectrum (185.4) 
and this further confirmed the successful synthesis of the ligand. The same 
consistency was observed from the mass spectra of the synthesized ligands, L1 and 
L3. The obtained mass spectrometry results were the indication that the substituted 
anilinopyridinate ligands had been successfully synthesized given that they matched 
their theoretical values.  
 
Figure 2.6: Mass spectrum of H(2-Meap)  
The purity of the anilinopyridinate ligands were ascertained by elemental analysis. The 
calculated CHN composition of H(2-Meap) is C, 78.23; H, 6.57; N,15.21 and the 
deviation is less than 0.4 % from elemental analysis, C, 78.15; H, 6.25; N,15.23. The 
0.4 % deviation of the calculated CHN values from the obtained CHN values means 
that the compound is pure and has all the expected atom composition. 
The ≤ deviation of the calculated CHN values from elemental analysis results was 
obtained from the other investigated.  This correlation was a confirmation that all three 
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ligands, Hap, H(2-Meap) and H(2-Fap), were successfully synthesized and 
characterized. 
2.2.2 Synthesis and characterization of mixed-ligand diruthenium 
complexes. 
There are various types of the mixed-ligand diruthenium complexes synthesized from 
a mixture of diruthenium tetracarboxylate with substituted bridging anilinopyridinate 
ligands.12 One example being the formation of four mixed ligand complexes, 
Ru2(OAc)x(L)4-xCl (x = 0-3) having different ratios of the acetate and anilinopyridinate 
ligand which is an unsymmetrical N,N’ donor bridging ligand.16 
Kadish and co-workers reported in studies that refluxing Ru2(OAc)4Cl with excess 2-
fluoroanilinopyridinate bridging ligand in methanol, under nitrogen for 3 hours results 
in the isolation of three mixed-ligand complexes; Ru2(OAc)3(Fap)Cl, 
Ru2(OAc)2(Fap)2Cl, Ru2(OAc)(Fap)3Cl and the fully substituted complex, 
Ru2(Fap)4Cl.15 This can be attributed to the stepwise metathesis displacement 
mechanism shown in equations 1 - 4.15 
 
Scheme 2.2: Stepwise metathesis displacement. 
The progress of the reaction was monitored on a thin layer chromatography and the 
derivatives separated on a silica column using 1:1-(v:v hexane/acetone) as eluent. 
Four fractions, two green, one blue and one purple were collected. The fractions had 
the following Rf values, 0.875, 0.825, 0.525 and 0.125 from the TLC and were 
identified as Ru2(Fap)4Cl (4), Ru2(OAc)(Fap)3Cl (3), Ru2(OAc)2(Fap)2Cl(2) and  
Ru2(OAc)3(Fap)Cl (2), respectively. The yields obtained for each of the compounds 
were reported to be, 30.20 (4), 20.10 (3), 24.20 (2) and 4.80 (1) %.15 
The UV/Visible spectrum of Ru2(OAc)x(Fap)4-xCl (x = 0-3) in CH2Cl2 reported is shown 
in figure 2.7. Each Ru25+ species exhibits a low-energy absorption in the 581-750 nm 
region which was attributed to an allowed charge-transition π (ligand, metal) to π*(Ru2) 
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or δ*(Ru2) and a less intense band around 415 - 513 nm. Moreover, the 
Ru2(OAc)3(Fap)Cl (x = 3) compound has a band at 990 nm which was assigned to a 
δ         δ* transition.16 The 580 - 800 nm transition was shown to be responsive to the 
type of bridging ligand coordinated to the dimetal core.17 
This is apparent as indicated by the wavelength shift of the major bands in the visible 
region of the absorption spectrum of the compound upon going from Ru2(OAc)3(Fap)Cl 
to Ru2(Fap)4Cl. It was also clear that the mixed ligand diruthenium derivatives with two 
or three Fap groups on the molecule exhibited spectroscopic behavior similar to the 
compound with four Fap ligands. However, the complex with only one Fap bridging 
ligand exhibited vastly different characteristics.  
This difference was attributed to the existence of chemical equilibria in solution which 
involved the associated and non-associated anionic axial ligand on the complex 
splitting at 580 – 650 nm for x = 3.16 Because of the different characteristics of mono-
substituted complexes in solution compared to the other derivatives, the mono-
substituted mixed ligand diruthenium complex became the complex of interest.  
 
Figure 2.7:  UV/Visible spectrum of Ru2(OAc)x(Fap) 4-xCl in CH2Cl2.15 
35 
 
In this work, various mono-substituted diruthenium complexes have been synthesized, 
whereby, an acetate bridging ligand was replaced by an incoming anilinopyridinate 
ligand as shown in scheme 2.2, eqn 1 - 4. The extent of the replacement of the acetate 
was controlled by varying the reaction conditions such as temperature, reaction time 
and choice of solvents.15 
By reacting Ru2(OAc)4Cl with a substituted anilinopyridinate ligand, it is possible to 
obtain a mono-substituted diruthenium complex only having one substituted 
anilinopyridinate ligand and three acetate ligands (scheme 2.2, eqn 1). To exclusively 
isolate a mono-substituted complex, reaction conditions such as temperature, reaction 
time and solvent type were optimized. The focus was on monitoring the reactions to 
avoid further substitution. In this case, UV/Visible spectroscopy was used to monitor 
the product formed. 
Prior to synthesizing the investigated mono-substituted complexes under reflux 
conditions, the compound, Ru2(OAc)4Cl with excess 2-fluoroanilinopyridinate bridging 
ligand reaction was first carried out at room temperature in cold methanol. This 
methodology was employed to prevent the formation of the subsequent reaction 
products, Ru2(OAc)2(L)2Cl, Ru2(OAc)(L)3Cl and Ru2(L)4Cl. Stirring the reaction for 30 
minutes did not result in any spectroscopic changes, the reaction was left to stir for a 
further 120 minutes which then started showing the formation of a product as shown 
in figure 2.8. 
From the UV/Visible spectral changes, it could be concluded that with time, more 
product was formed hence the mixture was left to react for 350 minutes in methanol 
at room temperature. Although a mono-substituted complex formed from the room 
temperature reaction, the yields were very low due to poor solubility of the starting 
materials in cold methanol. Furthermore, the room temperature method required a 
longer reaction time.  
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Figure 2.8: Monitoring of Ru2(OAc)3(2-Fap)Cl by UV/Visible spectroscopy at room 
temperature. 
Although the room temperature synthesis resulted in low yields due to poor solubility, 
the findings led to the suggestion that solubility could be improved by synthesizing 
these complexes at higher temperatures. In this study, we have synthesized and 
isolated complexes of the type Ru2(OAc)3(L)Cl, (L = ap, 2-Meap and 2-Fap). By 
optimizing the reaction time, temperature and solvent type, we managed to exclusively 
isolate only the mono-substituted mixed-ligand diruthenium complexes.   
The synthesis and characterization of mixed-ligand diruthenium complexes, 
Ru2(OAc)3(ap)Cl, Ru2(OAc)3(2-Meap)Cl and Ru2(OAc)3(2-Fap)Cl are discussed in this 
section. A diruthenium tetracarboxylate compound, Ru2(OAc)4Cl, was used as a 
starting material for the synthesis of the investigated mixed-ligand diruthenium 
complexes and this precursor was synthesized following a procedure reported in 
literature.1,18 
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The complexes, Ru2(OAc)3(ap)Cl, Ru2(OAc)3(2-Meap)Cl and Ru2(OAc)3(2-Fap)Cl 
were prepared using the same procedure,15 by refluxing a mixture of Ru2(OAc)4Cl and 
substituted aniline in methanol for 90 minutes.  The progresses of the reactions were 
monitored on a thin layer chromatography plate using ethyl acetate as an eluent. 
During the reactions, the brown homogeneous solution changed into a blue-green 
solution. After completion of the reactions, the solutions were concentrated using a 
rotary evaporator. This was followed by adding 100 ml of CH2Cl2 to remove unreacted 
diruthenium tetracarboxylate. The solution was concentrated, and the residue purified 
by column chromatography using ethyl acetate as an eluent. Three bands, green, 
brown and blue were observed and collected.  
After analysis of the fractions on a TLC plate and by mass spectrometry, it was 
concluded that the blue fraction is the compound of interest. The solvent was then 
removed using a rotary evaporator and was dried on a high vacuum pump to isolate 
blue products. The compounds were obtained in yields of 62 % for Ru2(OAc)3(ap)Cl, 
59 % for Ru2(OAc)3(2-Meap)Cl and 48 % for Ru2(OAc)3(2-Fap)Cl. The mono-
substituted diruthenium complexes are air stable and show good solubility in 
dichloromethane, methanol, ethyl acetate and acetonitrile. 
The investigated complexes are all insoluble in hexane. Ru2(OAc)3(2-Meap)Cl is 
soluble in DMSO and H2O whereas Ru2(OAc)3(ap)Cl is partially soluble in these 
solvents (DMSO and H2O). Ru2(OAc)3(2-Fap)Cl is insoluble in DMSO and H2O. These 
complexes are paramagnetic because they have three unpaired electrons at the π* 
and δ* orbitals, therefore, they could not be characterized using NMR spectroscopy. 
Mass spectrometry, UV/Visible and FTIR spectroscopy were all used to analyze the 
compounds. Elemental analysis was used to ascertain purity of the complexes. The 
investigated complexes have the Ru25+ diruthenium core and are shown in figure 2.9.   
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Figure 2.9: Structures of the synthesized complexes, Ru2(OAc)3(ap)Cl (C1), 
Ru2(OAc)3(2-Meap)Cl (C2) and Ru2(OAc)3(2-Fap)Cl (C3).  
 
2.2.2.1 Characterization of mixed-ligand diruthenium complexes with FTIR. 
FTIR analyses were conducted to investigate if complexation had occurred through 
the pyridino nitrogen, anilino nitrogen and the dimetal core. This was done under the 
premise that upon complexation, the anilinopyridinate (N-H) stretch would disappear. 
Indeed, this was observed on the FTIR spectrum of the Ru2(OAc)3(2-Meap)Cl complex 
(figure 2.10), where it was observed that the complex did not have a (N-H) vibration 
stretch at 3247 cm-1 which is present on the FTIR spectrum of the Hap ligand.  
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A stretch appearing at 3070 cm-1 was characterized to the (C-H) frequency stretch of 
the anilinopyridinate ligand, Hap. The FTIR spectrum also shows a band at 1589 cm-
1 for the (C=N) stretching frequency of the pyridino ring as well as (C-C) stretching 
frequency at 1463 cm-1 present in both the ligand and complex FTIR spectrum. The 
strong stretching frequency at 400 cm-1 which does not occur in the ligand spectrum 
was also an indication that the acetate ligands were still coordinated, and that the 
desired compound was formed. The trend that the N-H stretch collapses upon 
complexation was observed for all the synthesized complexes. This indicates the 
successful coordination of the dimetal core to the anilino and pyridino nitrogen of the 
anilinopyridinate ligand.  
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Figure 2.10: FTIR spectrum of free ligand, H(2-Meap) and mixed-ligand diruthenium 
complex, Ru2(OAc)3(2-Meap)Cl. 
 
2.2.2.2 Mass spectrometry + CHN analysis of diruthenium complexes. 
Mass spectrometry was conducted to investigate that the compounds had been 
successfully synthesized. The mass spectra shown in figure 2.11 shows that one 
fraction is predominant with [M+H]+ (fragment)] of 594.8 which matched the calculated 
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molar mass of the complex Ru2(OAc)3(2-Meap)Cl, 593.2 g.mol-1. The spectrum shows 
a minor peak with the value of 560 g.mol-1, this value amounts to the molar mass of 
the compound without the chloride anion. The observation further confirmed the 
hypothesis that there is two forms of the compound in solution, the non-associated, 
[Ru2(OAc)3(2-Meap)]+ and associated, Ru2(OAc)3(2-Meap)Cl compound.  
MS analyses were also performed on Ru2(OAc)3(ap)Cl and the major peak [M + H]+ 
(fragment)] was found to be 584.2.The molar mass of the target complex 
[(Ru2(OAc)3(ap)Cl)]+ was calculated to be 583.2 g.mol-1 which matched the empirical 
value obtained from mass spectrometry. For the Ru2(OAc)3(2-Fap)Cl complex, It was 
observed that the [M + H]+ (fragment)] (601.2 g.mol-1) was consistent with the 
calculated value of the target compound (600.2 g.mol-1). 
A good correlation between elemental analysis and the calculated CHN values of the 
investigated complexes was obtained. This implies that purifying the mixed-ligand 
complexes on a column chromatography were a success and that the expected 
composition of the complexes was obtained.  
 
 
Figure 2.11: Mass spectrum of Ru2(OAc)3(2-Meap)Cl.  
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2.2.2.3 UV/Visible spectroscopy of diruthenium complexes. 
In our study, three mixed-ligand diruthenium complexes, Ru2(OAc)3(ap)Cl, 
Ru2(OAc)3(2-Meap)Cl and Ru2(OAc)3(2-Fap)Cl have been investigated as to their 
spectroscopic behavior. The major peaks of the synthesized complexes occurred at 
similar wavelengths and have similar extension coefficients as those that were 
reported in literature (figure 2.7).15 Therefore, the accompanying transitions could be 
assigned: the split band with the range at 581 and 680 nm can be attributed to an 
allowed charge-transfer transition π (ligand, metal)       π*(Ru2) or δ* (Ru2), and the 
band approximately 950 nm band of all three complexes assigned to an allowed δ to          
δ* transition.  
The complexes were all studied in solution and the resulting spectra are shown in 
figure 2.12. In the case of the mixed-ligand complex with an unsubstituted 
anilinopyridinate compound, Ru2(OAc)3(ap)Cl, we see an increased intensity for the 
band at 666 nm and a shoulder at 590 nm (figure 2.12(C1)). This is the opposite of 
what was observed from the Fap containing complex. The difference was expected 
because the Ru2(OAc)3(ap)Cl complex is without an electronegative substituent at the 
ortho position. Therefore, the increased electron density around the dimetal core due 
to the electronegative anilino nitrogen results in the axial chloride ligand loosely bound 
to the dimetal core, favouring the positively charged species, [Ru2(OAc)3(ap)]+ in 
solution. This observation means that there is more of the species, [Ru2(OAc)3(ap)]+ 
than Ru2(OAc)3(ap)Cl in solution. Therefore, the proposed equilibrium of this complex 
in solution is:  
 
It is observed from the UV/Visible spectrum of the complex, Ru2(OAc)3(2-Meap)Cl, in 
figure 2.12 (C2) that it was no clear indication as to which form is dominant in solution. 
The broad band between 602 and 656 nm could mean that there is an equal amount 
of the two forms, [Ru2(OAc)3(2-Meap)]+ and Ru2(OAc)3(2-Meap)Cl in solution. The 
chemical equilibrium of the compound in solution is then suggested to be: 
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The UV/Visible spectroscopic behaviour of Ru2(OAc)3(2-Fap)Cl is shown in figure 2.12 
(C3). Herewith, a split band between 588 and 678 nm as well as a weak band at 955 
nm were observed. These bands do not appear on the UV/Visible spectra of further 
substituted products i.e. they appear for only mono-substituted products (see figure 
2.7). Based on each spectrum (figure 2.12), the complexes have different 
characteristics around the split band (580 – 680 nm) region. This indicates that the 
type of substituent on the anilino ring of the ligand plays a role in determining the type 
of form the compound exists in when in solution.  
For instance, in the case of Ru2(OAc)3(2-Fap)Cl compound,  the band at 588 nm is 
more intense than the band at 678 nm. The split band indicates an overlapping of two 
bands, meaning that there are two forms of this compound in solution and one is in 
greater amounts as compared to the other. The Ru2(OAc)3(2-Fap)Cl compound 
contains an electronegative substituent, fluorine. This electron withdrawing substituent 
decreases the electron density around the anilino nitrogen bridged with the ruthenium 
metal, which in turn strengthens the coordination of the axial chloride anion bound to 
the dimetal unit. The fluorine withdrawing substituent has an effect on the dimetal core 
such that the species, [Ru2(OAc)3(2-Fap)Cl] is favoured in solution. This explains the 
increased absorbance of the band at 588 nm and a shoulder at 678 nm. Therefore, 
the proposed equilibrium of the complex, Ru2(OAc)3(2-Fap)Cl in solution is:  
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Figure 2.12: UV/Visible spectra of Ru2(OAc)3(ap)Cl(C1), Ru2(OAc)3(2-Meap)Cl(C2),  
Ru2(OAc)3(2-Fap)Cl(C3). 
 
Table 2.1: UV/Visible peaks of the synthesized complexes.  
Compound 
λmax, nm, (ε x 10-3 mol.cm-1) 
Band 1 Band 2 Band 3 Band 4 Band 5 
C1 414(3.27) 464(3.18) 590(3.50) 666(3.46) 956(2.69) 
C2 417(3.23) 466(3.15) 602(3.52) 656(3.47) 952(2.80) 
C3 417(3.05) 472(2.92) 588(3.25) 678(3.26) 955(2.57) 
2.3 Ru2(OAc)3(L)Cl with excess halides 
It has been reported on one of the fully substituted diruthenium complexes, 
Ru2(F3ap)4Cl (F3ap = 2,4,6-trifluoroanilinopyridinate anion) that the compound can 
axially bind another Cl- to give, [Ru2(F3ap)4Cl2]- in solution.15 Based on the findings, it 
was gathered that ion binding could occur for the presently investigated complexes in 
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the presence of tetrabutylammonium chloride (TBACl) and tetraethylammonium 
bromide (TEABr), subsequently.  
From the UV/Visible spectral results of the synthesized mono-substituted complexes, 
it could be concluded that the compounds exist in two forms, [Ru2(OAc)3(L)Cl] and 
[Ru2(OAc)3(L)]+ in solution. Furthermore, it was shown that that the band at 580-599 
nm was as a result of the coordinated species whereas that at 648-690 nm was from 
the non-coordinated species. In order to prove this hypothesis, excess of halide ions, 
i.e. Cl- and Br- from TBACl and TEABr, respectively, were each added to a series of 
solutions containing the five complexes investigated and UV/Visible measurements 
were taken.  
In order to study the behaviour of the investigated diruthenium complexes in solution, 
quaternary ammonium salts such as (TBACl) and (TEABr) were added 
separately.19This procedure was done by preparing 4 x 10 -4 M concentration of the 
complexes, Ru2(OAc)3(L)Cl, as well as 0.01 M of TBACl and TEABr in separate flasks. 
From the prepared samples, about 3.60 ml of the compound was placed in a quartz 
cuvette and the UV/Visible spectroscopy was measured. This was followed by an 
addition of 0.5 ml TBACl to the same cuvette and the spectroscopic measurement was 
taken for all the investigated complexes. The same process was employed using 
TEABr instead of TBACl. 
UV/Visible spectroscopy measurements of the complexes before and after the addition 
of TBACl and TEABr were conducted and the results are presented in figure 2.13. The 
addition of TBACl to C1 resulted in the band at 666 nm collapsing and that at 590 nm 
increasing in intensity (figure 2.13). A similar response was observed when TBACl 
was added to C2 (figure 2.13). Herewith, it was observed that the equilibrium shifted 
to the 602 nm region. The difference between C1 and C2 UV/Visible spectra can be 
attributed to the fact that C2 contains an electron donating group, CH3 at the ortho 
position of the nitrogen anilino ring whereas C1 is without an electron donating group 
at that position.  
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The same behaviour was observed when TBACl was added to C3, it resulted in a 
collapse of the band at 678 nm and an increase in intensity of the band at 588 nm 
(figure 2.13). The addition of TEABr to the same compound (C3) yielded similar results 
as seen in figure 2.13.  
 
Figure 2.13: UV/Visible spectra of Ru2(OAc)3(ap)Cl (C1), Ru2(OAc)3(2-Meap)Cl (C2) 
and Ru2(OAc)3(2-Fap)Cl (C3) in neat CH2Cl2 with TBACl (red) and in neat CH2Cl2 
with TEABr (blue). 
The change in the spectrum after the addition of the halide ions indicated that some 
of the ions bind to the complex. This observation was supported by Le Chatelier`s 
principle as the association of chloride is promoted to decrease the concentration of 
free ions in solution. To further confirm that these compounds behaved in a similar 
manner when exposed to other anions in solution, TEABr was introduced and the 
results were similar to those of TBACl (a collapse of 580 – 599 nm and an increase in 
intensity of 648 – 690 nm). In addition, the addition of halide anions resulted in the 
disappearance of the weak band at 940-980 nm. 
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It is interesting to note that whilst the bands may have increased in intensity or collapse 
after a substitution of the axial ligand, the peak position of the band did not shift. This 
means that the substitution of the axial ligand does not change the peak position but 
changing the equatorial ligand results in a peak shift. The change in the spectral 
behaviour upon the addition of the quaternary ammonium halide salts (TBACl & 
TEABr) indicated the presence of two species in solution and confirmed the hypothesis 
that mono-substituted mixed-ligand diruthenium complexes have different 
spectroscopic properties compared to the other three derivatives, Ru2(L)4Cl, 
Ru2(OAc)2(L)2Cl and Ru2(OAc)(L)3Cl.  
The conclusion is that the complexes under investigation exist in two forms, 
Ru2(OAc)3(L)Cl and [Ru2(OAc)3(L)]+ in solution before the addition of halide anionic 
ligands. After the addition of the salts, the spectra changes as the band at 593 nm 
becomes more pronounced while the shoulder at 661 nm collapses.  
The information obtained from UV/Visible spectroscopy indicates that there was a 
formation of new species involving the coordination of the newly introduced halide. 
The identity of the species may be Ru2(OAc)3(L)X or [Ru2(OAc)3(L)X2]– as suggested 
by Kadish et al.15 Below is the equilibrium in solution showing different characteristics 
before and after the addition of halide anions:  
 
2.4 Halide abstraction experiments 
Following the successful isolation and characterization of mixed-ligand diruthenium 
complexes, Ru2(OAc)3(ap)Cl, Ru2(OAc)3(2-Meap)Cl and Ru2(OAc)3(2-Fap)Cl. The 
next step was to create anionic systems out of the synthesized complexes. Studies 
show that reacting a mixed-ligand diruthenium complex with a silver containing 
reagent should precipitate out in the form of AgCl  resulting in an outer-sphere 
positively charged compound.20 
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The goal of the study was to develop diruthenium compounds that are soluble in 
aqueous solvents such as DMSO and H2O. To understand the influence of structural 
changes on the biological activity of these compounds as metallodrugs, the dimetal 
core was modified by abstracting the axial ligand (Cl-). A structure of the complex with 
the axial ligand undergoing structural modification is shown in scheme 2.3. 
 
 
Scheme 2.3: Modification of a substituted diruthenium complex. 
Three complexes, Ru2(OAc)3(ap)Cl, Ru2(OAc)3(2-Meap)Cl and Ru2(OAc)3(2-Fap)Cl 
were used as representatives to study the effect silver tetrafluoroborate (AgBF4) has 
on the dimetal unit and to test a suitable alcohol solvent  for every type of a mono-
substituted mixed-ligand diruthenium complex. The modified complexes, 
[Ru2(OAc)3(L)]+BF4-, were compared to the neutral diruthenium complexes, 
Ru2(OAc)3(L)Cl by UV/Visible spectroscopy to study the effect chloride abstraction has 
on the dimetal core (figure. 2.14). 
 
2.4.1 UV/Visible spectroscopy of cationic diruthenium complexes. 
UV/Visible spectroscopy measurements of the complexes, Ru2(OAc)3(ap)Cl, 
Ru2(OAc)3(2-Fap)Cl and Ru2(OAc)3(2-Meap)Cl in different solvents, EtOH, MeOH and 
i-PrOH are shown below. The Ru2(OAc)3(2-Fap)Cl complex is insoluble in iso-
propanol hence ethanol was used. A 1:1 molar reaction of this compound with AgBF4 
shows a shift in equilibrium whereby the original spectrum shows one form, 
Ru2(OAc)3(2-Fap)Cl dominant in solution. After the chloride anion abstraction, the 
intensity of the band at 660 nm increased whereas that at 590 nm decreased.  
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The reaction of Ru2(OAc)3(ap)Cl with AgBF4 in iso-propanol proved to favour the 
dissociated species, [Ru2(OAc)3(ap)]+ in solution. From TBACl and TEABr tritrations, 
we could conclude that the addition of a halide anion favours the coordinated species 
in solution. The opposite was observed upon the addition of AgBF4 whereby, a 
decrease in intensity of the peak at 588 nm and an increase in intensity of 678 nm 
band were observed. This implies that reactions of these complexes with AgBF4 has 
an impact on the dimetal core as evidenced by UV/Visible spectroscopy (figure 2.14).  
For the Ru2(OAc)3(2-Meap)Cl complex, reaction with AgBF4 in iso-propanol also 
proved to favour the positively charged species, [Ru2(OAc)3(2-Meap)]+ in solution. 
However, the peak at 602 nm was still present but it was not well defined, this was a 
positive sign because it confirmed that with time and a different solvent type, the 
chloride anion can be removed altogether leaving only the charged species in solution.  
 
Figure 2.14: UV/Visible spectra of Ru2(OAc)3(ap)Cl in i-prOH  , Ru2(OAc)3(2-
Meap)Cl in i-prOH and Ru2(OAc)3(2-Fap)Cl in etOH after reacting with AgBF4.  
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The UV/Visible spectral changes discussed above confirmed that reaction of mixed-
ligand diruthenium complexes with AgBF4 results in changes in the behaviour of the 
species in solution. According to the results obtained from UV/Visible spectra, it is 
evident that the AgBF4 is a good reagent for chloride axial abstraction, and that 
optimizing reaction time and solvent type can completely remove the halide anion (Cl-
) from the diruthenium unit.  
2.5 Conductivity studies 
To further study the nature of the investigated complexes, molar conductivities were 
measured in different solvents, MeOH, EtOH and i-PrOH. Conductivity measurements 
have normally been used in complexes coordinated to various ligands to test their 
solubility in different solvents. The degree of ionization of the complex can be provided 
by measuring its conductivity.21 This was done under the premise that soluble 
complexes will have a higher molar conductivity as compared to partially or non-
soluble complexes. A higher molar conductivity implies that the complex liberates 
molecular ions in solution.22 
The molar conductivities of the three compounds were found to be in the electrolytic 
range 4-12 µs. It is clear from the conductivity data that the complex containing an 
electronegative substituent, F, is more soluble in MeOH and this is because the 
compound is more polar, therefore, expected to dissolve in polar solvents because 
‘’like dissolves like’’. 
2.6 Conclusions 
Mixed-ligand diruthenium complexes were successfully synthesized and 
characterized as to their spectroscopic properties. These compounds were prepared 
in a stepwise metathesis displacement reaction by reacting tetracarboxylate 
compound with HL in refluxing methanol. Mono-substituted diruthenium complexes 
were found to exhibit different spectroscopic behavior in solution as compared to the 
further substituted diruthenium complexes, Ru2(OAc)2(L)2Cl, Ru2(OAc)(L)2Cl and 
Ru2(L)4Cl. 
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The difference is seen on the UV/Visible spectra where there is an overlapping of two 
peaks, resulting in a shoulder at the 640 nm region, this behavior was attributed to the 
existence of chemical equilibrium involving the association and dissociation of the 
anionic axial ligand of the neutral complex. 
The change in the UV/Visible spectra after the addition of the quaternary halide salt, 
TBACl and TEABr indicates the presence of two species in solution which is a 
characteristic of mono-substituted mixed-ligand diruthenium complexes. Electron 
withdrawing containing diruthenium complexes show good solubility in polar solvents 
such as MeOH whereas methyl containing diruthenium complexes are soluble in 
slightly polar solvents; the observations agree with conductivity measurements.  
2.7 Experimental 
2.7.1 Materials and instrumentation 
The reagents, 2-bromopyridine and all the substituted anilines (aniline, 2-fluoroaniline 
and 2-methylaniline) were purchased from Sigma-Aldrich and were used as received. 
All solvents, acetonitrile, acetone, chloroform, dichloromethane, ethanol, ethyl acetate, 
hexane, iso-propanol and methanol were purchased from Sigma-Aldrich and were 
distilled before use. Silica gel (Merck 230-400 mesh 60 Å) was purchased from sorbent 
technologies and used as received. Tetra-n-butylammonium chloride (TBACl), 
tetraethylammonium bromine (TEABr) and tetra-n-butylammonium perchlorate 
(TBAP) were purchased from Sigma-Aldrich and were used without further purification. 
Silver trifluoroborate (AgBF4) was purchased from Sigma-Aldrich.  
The NMR spectra were recorded on a Bruker Avance 300 MHz and 500 MHz. The 
infrared spectra were recorded on a Bruker FTIR spectrometer. Mass spectrometry 
was performed using Advison Expression L compact. CHNS elemental microanalysis 
was performed on a Flash 2000 CHNS-O Analyzer fitted with an Auto sampler. 
UV/Visible spectroscopy experiments were carried out with a BASi instrument.  
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2.7.2 Ligand synthesis 
2.7.2.1 Synthesis of Hap 
2-Bromopyridine (13.00 ml; 0.136mol) and aniline (25.00ml; 0.273 mol) were placed 
in a 250 ml round-bottom flask equipped with a condenser and magnetic stirring bar. 
The mixture was heated at 170 °C for 9 hours. During the reaction, the mixture 
changed colour from transparent yellow to purple. Upon completion of the reaction, 
10% NaOH (100 ml) was added to the flask, and the mixture was stirred for a further 
15 minutes at room temperature. The contents of the flask were then steam distilled.  
The residue remaining in the flask was extracted with CH2Cl2 (3 x 50 ml). The organic 
phase was then collected and dried with MgSO4. The CH2Cl2 distilled with a rotary 
evaporator and the deposit was recrystallized with boiling hexane to afford white 
crystals. Yield:20.16 g, 87 %. [m/z (fragment)]: 171.0 [Hap]+.1H NMR in CDCl3: 8.24(d, 
Ha), 7.53(dd, Hc), 7.35(d, He;Hf), 7.05(m, Hg), 6.90(d, Hd), 6.50(dd, Hb), 6.50(s, NH) 
ppm.13C NMR: 108.3, 115.0, 120.40, 122.8, 129.3, 137.50, 140.4, 148.35, 156.03 
ppm. FTIR (cm-1): (N-H) 3247,(C-H) 307, (C=N) 1589, (C-C) 1463. Anal. Calc for 
C11H10N2: C, 77.62; H, 5.92, N, 16.46. Found: C, 77.55, H, 5.24, N, 16.74. 
2.7.2.2 Synthesis of H(2-Meap) 
2-Methylaniline (30.00 ml; 0.282 mol) and 2-bromopyridine (15.00 ml; 0.157 mol) in a 
250 ml round bottom flask at 170 °C for 14 hours. During the reaction, the contents of 
the round bottom flask were observed to have changed colour form transparent yellow 
to brown-orange. At the end of the reaction, 10% NaOH (100 ml) was added to the 
reaction mixture. The product was then steam distilled and the crude product that 
remained in the flask was extracted with CH2Cl2 (3 x 50 ml). The organic phase was 
collected and dried with MgSO4.  
This was followed by the removal of the solvent using a rotary evaporator and the 
resulting residue was recrystallized with boiling hexane and white crystals were 
isolated and dried under high vacuum. Yield:27.48 g, 95 %. [m/z (fragment)]: 185.40 
[H(2-Meap)]+. 1H NMR in CDCl3: 8.10(d, Hh), 7.43(td, Hc; Hf), 7.18(m,He;Hd), 7.05(d, 
Ha), 6.62 (m, Hg;Hb), 6.30(s, NH), 2.23(s, CH3) ppm. 13C NMR: 18.00, 107.5, 114.00, 
122.40, 124.3, 127.40, 132.21, 133.58, 135.66, 137.32, 148.54, 155.5 ppm. FTIR (cm-
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1): (N-H) 3155, (C-H) 2941, (C=N) 1527, (C-C) 1425. Anal. Calc for C12H12N2: C, 
78.23; H, 6.57, N, 15.21. Found: C, 78.15, H, 6.25, N, 15.23. 
2.7.2.3 Synthesis of H(2-Fap) 
2-Fluoroaniline (25.00 ml; 0.258 mol) and 2-bromopyridine (13.00 ml; 0.136 mol) were 
placed in a 250 ml round-bottom flask equipped with a condenser and a magnetic 
stirrer bar. The homogeneous mixture was heated at 170 °C overnight. A colour 
changed from yellow to purple was observed. 10% NaOH (100 ml) was added to the 
mixture, which was stirred for a further 15 minutes at room temperature. The mixture 
was steam distilled and the crude product was extracted withCH2Cl2 (3 x 50 ml) and 
the organic phase was collected and dried with MgSO4.  
The solvent was removed with a rotary evaporator and the residue was recrystallized 
with hot hexane to afford white crystals. Yield: 21.70 g, 85%. [m/z (fragment)]: 
189.1[H(2-Fap)]+.1H NMR in CDCl3: 8.26(d, Ha), 8.04(dd,Hc), 7.54(m, Hb), 7.15(m, 
Hh;He), 7.00(m, Hf), 6.80 (dd, Hd;Hg), 6.65(s, NH) ppm. 13C NMR 109.90, 115.25, 
115.41, 115.51, 121.05, 122.55, 122.60, 124.38, 124.42, 128.83, 128.85, 137.81, 
147.88, 154.51, 155.30, 155.60 ppm. FTIR (cm-1): (N-H) 3257, (C-H) 2991, (C=N) 
1682, (C-C) 480. Anal. Calc for C11H9N2F: C, 70.20; H, 4.82; N, 14.88. Found: C, 
70.18; H, 4.66; N, 15.18. 
2.7.3 Complex synthesis 
2.7.3.1 Synthesis of Ru2(OAc)4Cl 
The precursor, Ru2(OAc)4Cl was successfully synthesized by stirring and refluxing 
RuCl3·3H2O (2.5 g, 0.012 mol) with LiCl (2.67 g, 0.062 mol) in a 42 ml solution of 17 
% acetic anhydride in glacial acetic acid. The dark brown reaction mixture was heated 
to 160 °C in a slow stream of oxygen for 16 hours. The reaction was left to cool in the 
refrigerator overnight and the solution changed colour from brown to military green.  
The precipitate was filtered and washed with glacial acid (2 x 40 ml).  
Red-brown micro crystals were isolated and dried. Yield: 4.59 g, 80 %. [m/z 
(fragment)]: 474.593 [(Ru2(OAc)4Cl)]+. FTIR data (cm-1): (COO)1403, (COO)1445.  
UV/Visible spectrum data in MeOH, (λmax, nm): 445. 
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2.7.3.2 Synthesis of Ru2(OAc)3(ap)Cl 
The Ru2(OAc)3(ap)Cl complex was synthesized by heating Ru2(OAc)4Cl (520 mg; 1.09 
mmol) and Hap (939 mg; 1.09 mmol) in methanol (100 ml) at 63 °C for 90 minutes. 
During the reaction, the solution changed colour from brown to blue-green. After the 
reaction had been completed, the resulting solution was concentrated, and the residue 
was washed with dichloromethane (3 x 40 ml).  
The resulting sample was isolated on a silica chromatography using ethyl acetate as 
an eluent. The fraction of interest was dried, and a blue powder was isolated. Yield: 
0.39 g, 62 %. [m/z (fragment)]: 584.80 [Ru2(OAc)3(ap)Cl]+, 549.34 [Ru2(OAc)3(ap)]+. 
Anal. Calc for Ru2C17O6H21N2Cl: C, 34.79; H, 3.61; N, 4.77. Found: C, 35.67; H, 3.54; 
N, 4.36.  
2.7.3.3 Synthesis of Ru2(OAc)3(2-Meap)Cl 
A mixture of Ru2(OAc)4Cl (512 mg; 1.08 mmol) and H(2-Meap) (200 mg; 1.08 mmol) 
in methanol (100 ml) was heated at 63 °C for 2 hours. During this period, the solution 
changed colour from brown to blue-green. The resulting solution was washed with 
dichloromethane (3 x 40 ml) to remove the unreacted diruthenium tetracarboxylate, 
(Ru2(OAc)4Cl). The filtrate was dried using a rotary evaporator.  
This was followed by purification on a column chromatography using silica gel as a 
stationery phase and ethyl acetate as an eluent. A blue solid was isolated. Yield: 0.37 
g, 59 %. [m/z (fragment)]: 594.20 [Ru2(OAc)3(2-Meap)Cl]+,558.74 [Ru2(OAc)3(2-
Meap)]+. Anal. Calc for Ru2C18O6H23N2Cl: C, 35.97; H, 3.86; N, 4.66. Found: C, 35.99; 
H, 3.87; N, 4.53.  
2.7.3.4 Synthesis of Ru2(OAc)3(2-Fap)Cl 
Ru2(OAc)4Cl (500 mg; 1.05 mmol) and H(2-Fap) (198 mg; 1.05 mmol) in methanol 
(100 ml) was heated at 63 °C for 90 minutes. The progress of the synthesis was 
monitored by thin-layer chromatography and ethyl acetate was used as an eluent. 
During this period, the solution changed colour from brown to blue-green and resulting 
suspension was washed with dichloromethane (3 x 40 ml) to remove unreacted 
starting material, [Ru2(OAc)4Cl].  
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The filtrate was dried using a rotary evaporator and this was followed by purification 
of the compound on a silica chromatography. The solvent was removed on a rotary 
evaporator and the residue was dried on a high vacuum pump to isolate a blue solid. 
Yield: 0.30 g, 48 %. [m/z (fragment)]: 601.20 [Ru2(OAc)3(2-Fap)Cl]+, 565.74 
[Ru2(OAc)3(2-Fap)]+. Anal. Calc for Ru2C17O6H20N2ClF: C, 33.15; H, 3.33; N, 4.63. 
Found: C, 33.51; H, 3.87; N, 3.60. 
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Chapter 3 
Electrochemistry of mixed-ligand diruthenium complexes 
3.1 Introduction  
Electrochemical characterization of  Ru25+ diruthenium complexes can undergo two-
metal centered oxidations and a one metal centered reduction to give  Ru26+, Ru27+ 
and Ru24+ oxidation states of the compound, respectively.1 This was observed under 
nitrogen atmosphere. Under CO atmospheric conditions, five oxidation states Ru26+, 
Ru25+, Ru24+, Ru23+, Ru22+ of the same compounds are accessible and it was found to 
be due to the substitution of CO with the axial ligand.1,2 CO coordination results in the 
stabilization of lower oxidation states due to molecular orbitals interactions of CO and 
d orbitals of the metal core.3 
It has been reported that systematic changes in the bridging ligands affects the redox 
potential of the dimetal core.2 The discovery led to the interest in investigating the 
effect different substituents have on the Ru25+ unit, and to monitor how  half-potentials 
(E1/2) vary moving from an electron donating to an electron withdrawing substituent.   
Previous studies have shown that there are four redox reactions for mixed-ligand 
diruthenium complexes with the general formula, Ru2(OAc)x(L)4-xCl (x = 1- 4).4 These 
compounds are mostly analyzed in non-aqueous solvents such as anhydrous 
acetonitrile, dichloromethane or benzonitrile and are always reversible, this 
corresponds to the reduction or oxidation processes of the dimetal unit.4 
The redox properties of the mixed-ligand diruthenium complexes can be altered by the 
electronic properties of the bridging ligands with different subtituents.5 These anionic 
bridging ligands have electron withdrawing or donating substituents at the ortho, meta 
and para position on the anilino ring of the ligand. The electronic factor of the ligand 
affects the axial ligand coordinated to the dimetal core. 4,5 
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Mixed-ligand diruthenium Ru25+ complexes with two or fewer acetate (OAc) groups 
were shown to exhibit one-electron reductions and oxidations in CH2Cl2 containing 0.1 
MTBAP under N2.6 A different electrochemical behaviour under the same conditions 
were observed for the mono-substituted diruthenium complex, Ru2(OAc)3(L)Cl, and 
this was attributed to the multiple equilibria that involves different forms of the axially 
coordinated ligand.6 
The goal of the study was to examine mono-substituted mixed-ligand diruthenium 
complexes with different substituents of the anilinopyridinate ligands. The complexes 
discussed in this section were synthesized from substituted anilinopyridinate ligand 
and Ru2(OAc)4Cl in boiling methanol. Redox chemistry of the mixed-ligand 
diruthenium complexes presented as Ru2(OAc)3(L)Cl, where L is one of the anionic 
bridging ligands (chapter 2, chart 2.2) are discussed.  
3.2 Results and discussion 
3.2.1 Redox activity of Fe(C5H5)2 at electrode surface 
Cyclic voltammetry is the most widely used voltammetric techniques for studying the 
redox behaviour of species in solution and for studying the reaction intermediates.7 
This technique is based on the measuring diffusion controlled current observed in an 
electrolysis cell. Upon the application of potential in an electrolysis cell which contains 
electroactive species, redox reactions occur at the electrode surface and current is 
generated.7 
The observed current at a particular potential is directly proportional to the 
concentration of the active species in the absence of interferences.8 A plot of current 
versus potential which is called a voltammogram is obtained and it gives analytical 
useful information on the analyte.8 In order to confirm diffusion control of the redox 
process, a small amount of ferrocene, roughly about 5 x10-5 M was dissolved in CH2Cl2 
containing 0.10 M TBAP as a supporting electrolyte. A cyclic voltammogram was 
carried out at different scan rates as shown in figure 3.1. 
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Figure 3.1: Cyclic voltammogram of ferrocene 
 
The Randles-sevcik equation ip = 0.4463nFAC(nFD/RT)1/2 where ip = current 
maximum, n= number of electrons transferred in the redox process, A= electrode area 
in cm2, F = Faraday constant in C mol-1, D = diffusion coefficient in cm2/s,  = Scan 
rate in mV/s, T = temperature and R = gas constant in K, predicts a linear relationship 
between ip and ()1/2 (figure 3.2).7,9 The regression was calculated to be R2 = 0.984 
which measures the linear relationship between current and scan rate, a value of R2 = 
0.984 implies linearity. This confirmed the accuracy of the machine and that it was 
diffusion controlled, therefore, the investigated compounds could be analyzed using 
cyclic voltammetry.  
 
 
 
 
60 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: An anodic current vs scan rate straight-line graph of ferrocene.  
 
3.2.2 Electrochemistry analysis of Ru25+ diruthenium complexes. 
Previous studies have reported on how the redox potential is affected by changing 
bridging ligands.10 Kadish reported on how the redox potential changes from moving 
from Ru2(ap-4-Meap)Cl to Ru2(2-Meap)4Cl as well as Ru2(L)4Cl compounds where L= 
2-Meap, 2-Fap, ap, 2,3-F2ap, 2,4-F2ap, 2,5-F2ap or 3,4-F2ap.10 The findings were that 
the position of the methyl substituent on the pyridyl group did not affect the structural 
framework; it however, greatly induced the lability of the axial Cl- ligand.10 The 
induction of the axial chloride results in changes in the electrochemical behaviour and 
redox activity of the compound.11 
The compound, Ru2(3,4-F2ap)4Cl in CH2Cl2 containing 0.1 M TBAP was analyzed 
under both N2 and CO atmosphere and compared with other compounds.  The cyclic 
voltammogram of this compound had similar shapes to that of the other compounds 
and it was observed that their half potentials (E1/2) for each electrode reaction, were 
dependent on the specific number and position of the substituent of the 
anilinopyridinate ligand.12  The other Ru2(L)4Cl under the same reaction conditions 
were found to undergo a single one-electron reduction under N2 but three one-electron 
reductions were observed under CO atmosphere.12 
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The reduction process of Ru2(dpf)4CO was accompanied by axial coordination and 
this resulted in the formation of two species in solution, Ru2(dpf)4CO/ [Ru2(dpf)4CO2]-
and it was observed that the E1/2 values shifted by 100 mV from the ones obtained 
under N2 atmosphere.13 The existence of two species in solution after the reduction 
process Ru25+/4+ of Ru2(dpf)4Cl under CO to give Ru2(dpf)4CO, and the irreversibility 
of the Ru2(3,4-F2ap)4Cl suggests a similar mechanism for all the Ru2(L)4Cl 
derivatives.13 It could also be concluded that, E1/2 depends on the electronic effect of 
the anilinopyridinate (ap) substituent.11,4 
Similar studies were conducted on mixed ligand diruthenium complexes, 
Ru2(OAc)x(Fap)x-4Cl (x = 1-4) where four derivatives were synthesized from a single 
reaction.6 These complexes show a reversible one-electron reduction and oxidation 
processes  in CH2Cl2 containing 0.10 M TBAP, for multiple substituted compounds with 
two or less acetate groups, (Ru2(OAc)2(Fap)2Cl, Ru2(OAc)(Fap)3Cl and Ru2(Fap)4Cl). 
A more complex behaviour was observed for a mixed-ligand diruthenium complex 
substituted by only one anilinopyridinate ligand (H(2-Fap)). This was due to the 
multiple equillibria (Ru2(OAc)3(L)Cl [Ru2(OAc)3(L)]+)   involving different 
forms of the axially coordinated chloride.6 
It was anticipated on the basis of our UV/Visible spectra (chapter 2, figure 2.12) that 
the axial Cl- ligand of the investigated complexes might dissociate and associate in 
solution from each Ru2(OAc)3(L)Cl to yield forms, Ru2(OAc)3(L)Cl and 
[Ru2(OAc)3(L)]+.In order to further qualify that hypothesis, cyclic voltammetry analyses 
of the complexes were performed. A representative characterization of the compound, 
Ru2(OAc)3(2-Fap)Cl by cyclic voltammetry  is discussed. Results with a similar 
consistency were obtained for the other complexes, Ru2(OAc)3(ap)Cl and 
Ru2(OAc)3(2-Meap)Cl and their half potential values are summarized in table 3.1. 
3.2.3 Characterization of Ru2(OAc)3(2-Fap)Cl by cyclic voltammogram 
Ru2(OAc)3(2-Fap)Cl was dissolved in CH2Cl2 containing 0.10 M TBAP under N2 
atmosphere to make up a 4x10-4 M solution and the cyclic voltammograms are shown 
in figure 3.3. The cyclic voltammogram of Ru2(OAc)3(2-Fap)Cl was recorded from 0 to 
1.60 V (figure 3.3). Herewith, two anodic potentials at 1.14 V and 1.29 V were 
observed. These potentials indicate that there is two forms, Ru2(OAc)3(2-Fap)Cl & 
[Ru2(OAc)3(2-Fap)]+ of the compound in solution. The Ru2(OAc)3(2-Fap)Cl species is 
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easier to oxidize whereas [Ru2(OAc)3(2-Fap)]+ harder to oxidize as it is already in its 
oxidized form. The first oxidation Ru25+/6+ process under N2 atmosphere is reversible 
and the anodic potential is coupled with the re-reduction peak whose Epc value is 0.90 
V. Once the chloride is in solution, the positively charged species, [Ru2(OAc)3(Fap)]+ 
coordinates the axial Cl- ligand and the anodic potential is 1.28 V. After re-oxidation, 
the chloride dissociated into solution hence there is one reversible peak (figure 3.3). 
 
These findings supported the assumption that there are two forms of the complex in 
CH2Cl2 containing 0.10 M TBAP. The two species could be the neutral and charged 
species, Ru2(OAc)3(2-Fap)Cl and [Ru2(OAc)3(2-Fap)]+. When the potential was 
increased to higher positive potentials, 0 to 1.60 V, the complex became more 
positively charged, which favoured the coordination of the chloride (figure. 3.3). This 
explained why multiple peaks were observed on figure 3.3and upon switching 
potentials, one peak disappeared (figure 3.3). A switch in potential resulted in the 
uncoordinated chloride coordinating; hence there is one reversible peak. The results 
imply that at higher positive potentials, there was a higher concentration of the 
coordinated complex in solution. 
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Reduction potentials were also applied to Ru2(OAc)3(2-Fap)Cl under the same 
conditions and it was observed that increasing the electron density kicks out the 
Figure 3.3: Oxidation cyclic voltammograms of Ru2(OAc)3(2-Fap)Cl in CH2Cl2 
containing 0.10 M TBAP at 0.10 V/s scan rate. 
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coordinated chloride resulting in a positively charged compound, [Ru2(OAc)3(2-Fap)]+ 
in solution. This species was reduced at a cathodic potential of -0.74 V and it is 
reversible. From the readings, it could be concluded that negative potentials favoured 
the dissociated species Ru2(OAc)3(2-Fap)]+.  
After reduction, when the compound got re-oxidised, the coordinated chloride ion 
dissociated from the ruthenium metal and the dissociated species became favoured. 
There was no electron transfer in the dissociated species but a chemical reaction, this 
is because it was in its oxidised form already; hence there was no reversibility of the 
species (figure 3.4). Similarly, Ru2(OAc)3(2-Fap)Cl is harder to reduce than 
Ru2(OAc)3(2-Fap)]+.  
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Figure 3.4: Reduction cyclic voltammogram of Ru2(OAc)3(2-Fap)Cl in CH2Cl2 
containing 0.10 M TBAP at 0.10 V/s scan rate. 
 
The results are in agreement with the findings that mono-substituted mixed-ligand 
diruthenium complexes have a more complex behaviour in solution as 2 anodic 
potentials, Epa were observed and assigned to the two forms, Ru2(OAc)3(2-Fap)Cl 
and [Ru2(OAc)3(2-Fap)]+ of the complex in solution.The proposed redox behaviour 
mechanism of the complex, Ru2(OAc)3(2-Fap)Cl in CH2Cl2 containing 0.10 M TBAP at 
0.10 V/s scan rate is shown below (scheme.3.1). The compound undergoes one 
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reversible oxidation state Ru25+/6+ and a reversible reduction process assigned to 
Ru25+/4+.  
 
Scheme 3.1: Reaction mechanism of Ru2(OAc)3(2-Fap)Cl 
 
The other investigated mixed-ligand diruthenium complexes show similar shaped 
voltammograms under N2 atmosphere with values of E1/2 for each electrode reaction, 
depending upon the number and position of substituent of the anilinopyridinate ligands 
(table 3.1). The complexes undergo a single reversible one-electron reduction in 
CH2Cl2 containing 0.1 M TBAP under N2.  
 
Table 3.1: Half-wave potentials for Ru25+/4+ and Ru25+/6+processes of Ru2(OAc)3(L)Cl 
in CH2Cl2 containing 0.1 M TBAP.  
 
Ru25+ compounds 
Ru25+/4+ Ru25+/6+ 
E1/2 ∆Epa E1/2 ∆Epa 
Ru2(OAc)3(ap)Cl -530 -167 800 149 
Ru2(OAc)3(2-Meap)Cl -490 180 1060 190 
Ru2(OAc)3(2-Fap)Cl -570 -260 1020 240 
aThe difference between anodic and cathodic peaks in potential (mV) 
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3.3 Conclusions 
Complexes of the type Ru2(OAc)3(L)Cl were examined as to their electrochemistry 
under N2. Each compound was converted to Ru26+ after their first oxidation and to 
Ru24+ after their first reduction. Results obtained from cyclic voltammetry were in 
agreement, showing that mono-substituted mixed-ligand diruthenium complexes exist 
in two forms in solution. Two anodic peak potentials were observed on the cyclic 
voltammograms confirming multiple equilibria involving different forms of the axially 
coordinated chloride.  
The compounds were analyzed under the same reaction conditions for comparison 
purposes. The oxidation properties vary from 0.85 V to 1.20 V in the case of 
compounds containing electron donating substituents, Ru2(OAc)3(2-Meap)Cl. As well 
as Ru2(OAc)3(ap)Cl, which is without an electron donating substituent. In the case of 
compounds containing electron withdrawing substituents, Ru2(OAc)3(2-Fap)Cl, the 
values were observed from 1.10 V to 1.60 V. This suggests that the type of bridging 
ligand is an important factor in controlling the redox properties of these compounds.   
The substitution of Fap by ap led to a slight positive potential shift for all redox 
processes. The Ru2(OAc)3(ap)Cl compound was easily oxidized as compared to the 
Ru2(OAc)3(2-Fap)Cl compound  and this led to the conclusion that electron 
withdrawing substituents require higher positive potentials for oxidation. The 
substituent of the anilinopyridinate ligand has an impact on the half-potential of the 
Ru25+ complexes. Varying the substituent type on the anilino ring of the ligand causes 
a shift of electron density from the dimetal core, anilino and pyridino ring and this 
results in the change in redox potential. 
3.4 Experimental 
3.4.1 Material and instrumentation 
Cyclic voltammetry was carried out at room temperature under N2 using a three-
electrode system on a BASI Epsilon potentiostat instrument. All the experiments were 
carried out in dichloromethane. Tetra-n-butlyammonium perchlorate (TBAP) was used 
as supporting electrolyte. The three-electrode system consisted of a glassy carbon 
working electrode, Ag/AgCl (sat`dNaCl) reference electrode and platinum auxiliary 
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electrode. Ferrocene was purchased from Sigma-Aldrich and was used as received. 
Tetra-n-butlyammonium perchlorate (TBAP) was purchased from Sigma- Aldrich and 
was stored in the desiccator prior use. Dichloromethane was purchased from Sigma-
Aldrich and was distilled over calcium hydride. All the freshly prepared solutions were 
degassed under nitrogen gas flow before experiments. 
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Chapter 4 
Cell proliferation studies: Preliminary screening against cancer 
4.1 Introduction 
Studies of transition metal complexes as anti-cancer agents have been an interesting 
area since the remarkable efficacy of cisplatin.1 This study focuses on the 
development of ruthenium containing compounds as anti-cancer agents. 
Monoruthemic compounds such as ImH[trans-ImDMSORuCl4], (NAMI-A) is one of the 
compounds undergoing clinical trials.2,3 This compound has successfully completed 
phase I clinical trials and functions by inhibiting a membrane protein kinase C, this 
action triggers a sequence of events that eventually causes the death of cancer cells.4 
The compound, NAMI-A was found to be one of the few agents that have shown 
favourable results for the treatment of lung tumors.3 
Other monoruthemic complexes that attracted a lot of interest as chemotherapeutic 
agents are ruthenium (II) complexes containing arene ligands.5 Studies of [(Ru(ɲ6-
C6H6)(DMSO)Cl2] show the ability of the compound to inhibit topoisomerase II activity.5 
This compound has three derivatives which can be prepared by substituting the DMSO 
ligand with 3-aminopyridine, p-aminobenzoic acid and aminoguanidine. 5 
The three analogues of the ruthenium complex show great efficacy against breast and 
colon carcinoma cells as compared to the parent ruthenium compound.6 The discovery 
suggested that substituting ligands coordinated to the metal core can enhance the 
efficacy against human breast cancer.7 
The diruthenium complex also examined for potential ant-cancer properties is 
diruthenium tetracarboxylates, Ru2(OAc)4Cl. This compound was found to be 
moderately active against P388 lymphocytic leukemia cell lines.8 The study provided 
information that the solubility of the tetracarboxylate diruthenium complex can be 
improved by changing the type of bridging ligand.9 
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4.2 Cytotoxicity studies of mono-substituted diruthenium complexes 
In this work, three mono-substituted diruthenium complexes, Ru2(OAc)3(2-Fap)Cl, 
Ru2(OAc)3(ap)Cl and  Ru2(OAc)3(2-Meap)Cl have been studied as potential anti-
cancer agents. This was done under the premise that diruthenium complexes 
containing anilinopyridinate ligands will exhibit different properties from those of the 
acetate ligands. The three compounds were analyzed using the same procedure as 
follows: 
Ruthenium compounds were tested for their cytotoxicity on adenocarcinoma MCF-7 
breast cancer cells using the thiazolyl blue tetrazolium bromide colorimetric assay 
(MTT assay).7 This assay was based on the reduction of yellow tetrazolium salt to 
purple formazan crystals by metabolically active cells. Cells were treated with varying 
concentrations of the compounds for 48 hours after which the viable cells were 
quantitated through their ability to convert yellow MTT to purple formazan. The 
formazan crystals were solubilized in detergent and the resultant absorbance was 
quantitated spectrophotometrically at 595nm. The absorbance data was fitted to a 
dose response curve from which an IC50 inhibitory concentration for the compound 
was determined. 
Analysis was done based on the fact that cells that were alive were capable of 
converting the MTT to formazan which is purple in colour. The purple colour on the 
well plate implied that the cells were alive. The purple colour was obtained and it was 
sampled as the baseline at 595nm.The introduction of ruthenium complexes under 
investigation resulted in a decrease in absorbance which was measured in reference 
to the DMSO. The decrease in absorbance was evidence that the compounds have 
the potential to inhibit cell replication. 
The cytotoxic effect of Ru2(OAc)3(L)Cl, (L= Fap, ap or Meap) on the adenocarcinoma 
MCF-7 breast cancer cell lines were examined using MTT assay.  A concentration of 
5 μM of Ru2(OAc)3(L)Cl was used to evaluate the survival rate of the cells for 24 and 
48 hours. The same procedure was repeated but with a concentration of 10μM of 
Ru2(OAc)3(L)Cl for 24 and 48 hours.  
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After 24 hours of 5 μM Ru2(OAc)3(2-Meap)Cl treatment, a strong dose of cell 
proliferation was observed. This cell inhibition was indicated by a great decrease of 
cells from 100 to 30% survival rate shown in figure 4.1. The same effect was observed 
when 5 μM Ru2(OAc)3(2-Fap)Cl was used, the metallodrug killed about 60 % of the 
cells in the well place after 24 hours. The use of Ru2(OAc)3(ap)Cl resulted in the killing 
of 50 % of the cells, less effective than the other 2 metallodrugs, Ru2(OAc)3(2-Fap)Cl 
and Ru2(OAc)3(2-Meap)Cl but the decrease in cell survival rate was evident that the 
drug also exhibit anti-cancer properties. 
The three compounds were examined for 48 hours and the increase in cell survival 
rate could be due to the replication of cells in the plate with time. For comparison and 
determination of factors that affect apoptosis, the concentration of the metallodrugs 
were increased to 10 μM. The results of the evaluation are shown in figure 4.2. 
Examination of Ru2(OAc)3(ap)Cl shows a decrease of 50 % cell survival rate for both 
24 and 48 hours. A strong cell proliferation was observed for the Ru2(OAc)3(2-Meap)Cl 
treatment, killing about 70 % of the cells for 24 hours.  
For the same compound, increasing incubation to 48 hours resulted in cell 
multiplication as an increase was from 30 % survival rate for 24 hours to 40 % survival 
rate for 48 hours.  The opposite was observed with the Ru2(OAc)3(2-Fap)Cl 
compound, the graph shows a great cell proliferation rate, killing about 73 % of the 
cells, this implies increasing examination time for the fluoro containing compound 
inhibits cell multiplication. At 24 hours, the compound only killed 50 % of the cells in 
the plate. From the survival percentages, we see that the Ru2(OAc)3(2-Meap)Cl is 
more effective against breast cancer stem cells as demonstrated by the decrease in 
the number of cells.   
Examination of the methyl containing complex shows a strong cell proliferation at lower 
and higher concentrations as well as at both times, 24 and 48 hours. The findings were 
expected because the Ru2(OAc)3(2-Meap)Cl compound is more soluble in aqueous 
media, DMSO and H2O whereas Ru2(OAc)3(ap)Cl is partially soluble in these solvents. 
Ru2(OAc)3(2-Fap)Cl is insoluble in DMSO and H2O, this is due to the electron 
withdrawing subtituent on the anilino ring of the ligand. 
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Figure 4.1: Survival rate of MCF-7 cell lines treated with Ru2 metallodrugs (5 μM) for 
24 & 48 hours.   
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Figure 4.2: Survival rate of MCF-7 cell lines treated with Ru2 metallodrugs (10 μM) 
for 24 & 48 hours.   
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Ruthenium compounds were successfully evaluated for their antiproliferative activity 
against MCF7 breast cancer cell line at single-dose concentrations of 5 µM and 10µM. 
Cisplatin and its analogues are some of the most commonly used anti-cancer drugs.11 
However, the side effects as well as multi-drug associated with this line of therapy 
could not be ignored.   
 
The desired compounds promise improved properties with better solubility as they 
dissolved in DMSO. Other metallodrugs that have attracted a lot of attention as 
chemotherapeutic agents are palladium complexes.11 These complexes were shown 
to exert anti-tumour activity in cells that resist platinum coordination complexes.11 The 
solubility of the synthesized complexes has shown that the compounds are effective 
as anti-cancer and can be tuned such that cancer cells are not resistant towards them,   
4.3 Conclusions 
These results show that mono-substituted mixed-ligand diruthenium complexes, 
Ru2(OAc)3(L)Cl exhibit anti-proliferation against breast cancer cells. Moreover, the 
type of substituent on the ortho position of the anilino ring has an impact on the 
solubility of the compound in DMSO. Ligand design is paramount in the development 
of anti-cancer drugs because the methyl containing compound was found to be soluble 
in aqueous media such as DMSO and H2O whereas Ru2(OAc)3(ap)Cl was partially 
soluble in these solvents.  
Furthermore, the findings indicate that the metallodrugs exert great anti-cancer growth 
against breast cancer cells even at low concentrations. Taken together, the study 
indicated that the mixed-ligand diruthenium complexes display cytotoxic effect against 
breast cancer cells and that the type of substituent on the anilino ring of the ligand has 
a great impact on the effectiveness of the complex as a drug. The study also suggests 
that the mono-substituted diruthenium compounds may be useful in the treatment of 
many different cancers. 
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4.4 Experimental 
4.4.1 Material and instrumentation 
Human breast adenocarcinoma MCF-7 (oestrogen receptor positive) cells were 
maintained in RPMI 1640 medium (Highveld Biological, Lyndhurst, UK).7 All media 
were supplemented with 10% fetal bovine serum (FBS), 100U/ml penicillin and 
100µg/ml streptomycin. Cells were maintained at 37°C in CO2 (5%) – air (95%) 
humidified incubator. 
4.4.2 Cytotoxicity assays 
Ruthenium compounds were dissolved in DMSO (0.50 ml) to give stock solution 
concentrations of 5 μM and 10 μM for each compound. The stock solutions were then 
separately added to the medium to give a master mix concentration such that the 
concentration of DMSO is kept consistent (0.1% in RPMI medium). Complexes were 
prepared to their appropriate concentration on the day of treatment and incubated for 
24 and 48 hours.  
4.4.2.1 24-hour treatment 
MCF7 breast cancer cell lines (4.5 x 103) were seeded in 96-well plates. After reaching 
60-80 % confluence, cell lines were treated with ruthenium compounds (10µM 
dissolved in 0.1%DMSO). DMSO was used as the vehicle control. The plate was 
incubated for 24 hours. After incubation period, MTT solution (10µl) was added to the 
96-wells and incubated for 4 hours. 4 hours later, the solubilizing agent (100µl) was 
added to the 96-wells and the plate was incubated overnight. Cytotoxicity of 
compounds was assessed by MTT assay (Roche, USA).10 
Absorbance (595nm) was determined and the mean cell viability was calculated as a 
percentage of the mean vehicle control. The experiment was conducted in triplicates 
for each period of treatment and was performed in quadruples for each test compound. 
The same procedure was followed for the 48 hours incubation.  
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4.4.2.2 Statistical analysis 
Data presented are mean ± SEM (standard error of the means) of two independent 
experiments and a value of P < 0.05 was accepted as statistically significant. The 
TTEST was used to compare the two experimental time frames 
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Chapter 5 
Summary and Future work 
 
5.1 Summary and Future work  
A series of metal-metal bonded diruthenium complexes, having four equatorial 
bridging ligands and one axial chloride group have been successfully synthesized and 
characterized using UV/Visible and FTIR spectroscopy, cyclic voltammetry, elemental 
analysis as well as mass spectrometry. Stoichiometric amounts of the unsymmetrical 
aninilinopyridinate derivatives were reacted with Ru2(OAc)4Cl in methanol to yield 
mono-substituted mixed-ligand diruthenium compounds with the general formula, 
Ru2(OAc)3(L)Cl. 
Each complex exhibited a band between the 581 and 668 nm region as well as a weak 
band at the 950 nm region which is a characteristic of mono-substituted diruthenium 
complexes. Complexation of the examined complexes was confirmed by FTIR 
spectroscopy as the (N-H) stretching frequency was expected to disappear upon 
complexation and this was indeed achieved for all the complexes.  
The electrochemical behavior of the compounds in solution under N2 was studied 
using cyclic voltammetry. Each compound was converted to Ru26+ in a one-electron 
transfer oxidation process and to Ru24+ in a one-electron transfer reduction process. 
Two anodic potential peaks, confirming the presence of two forms in solution were 
observed. Cyclic voltammogram is dependent on the type of substituent of the 
anilinopyridinate ligand as the chemical equilibrium shifted depending on how electron 
withdrawing/donating the substituent is.   
The change in the spectra after the addition of TBACl and TEABr was an indication 
that there is a presence of two species of the compound in solution. The addition of a 
halide anion (Cl-, Br-) resulted in a shoulder at 643 nm collapsing and that at 581 nm 
becoming more pronounced. This indicated the formation of a species involving the 
co-ordination of the newly formed halide. The identity of the species may be 
Ru2(OAc)3(L)X or [Ru2(OAc)3(X2)]- as suggested by Kadish and co-workers.  
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Our cytotoxicity studies results show that the complexes of the formula, 
Ru2(OAc)3(L)Cl have a cytotoxic effect against breast cancer stem cells. The methyl 
containing complex displayed a low survival rate of the cells, meaning that it killed 
majority of the cells.The Ru2(OAc)3(2-Meap)Cl complex is soluble in aqueous media 
(DMSO and H2O)and has shown anti-neoplastic activity against tumor cells. 
 
Although the axial chloride ligand was not completely dissociated, there was a clear 
indication from UV/Visible spectra that reaction with AgBF4 results in a spectral change 
as the band at 666 nm became more pronounced and that at 581 nm less intense. In 
future, a bulkier silver salt and a non-coordinating solvent should be used to avoid 
coordination to the dimetal core as this has an impact on the spectroscopic behavior 
in solution.  
The investigated complexes promise to be effective anti-cancer agents, in future, a 
series of these complexes will be synthesized and characterized. It is also important 
to study the effect the position of the subtituent has on the dimetal core of the 
compound. Moreover, our study focused on examining the complexes on breast 
cancer cells, it is recommended that their effectiveness is studied on a spectrum of 
cancers.  
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6.1 Appendix 
Characterization of anilinopyridinate ligands 
 
Figure 1x: Mass spectrum of H(2-Fap).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2x: FTIR spectrum of H(2-Fap). 
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Figure 3x: Mass spectrum of Hap 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4x: FTIR spectrum of Hap. 
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Figure 5x: 1H NMR spectrum of H(2-Meap) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6x: FTIR spectrum of H(2-Meap). 
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Diruthenium complexes characterization 
 
 
Figure 7x: Mass spectrum of Ru2(OAc)4Cl  
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Figure 8x: FTIR spectrum of Ru2(OAc)4Cl 
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Figure 9x: UV/Visible spectrum of Ru2(OAc)4Cl in MeOH 
 
 
Figure 10x: Mass spectrum of Ru2(OAc)3(2-Fap)Cl 
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Figure 11x: FTIR spectrum of free ligand, H(2-Fap) and mixed-ligand diruthenium 
complex, Ru2(OAc)3(2-Fap)Cl. 
 
 
Figure 12x: Mass spectrometry of Ru2(OAc)3(ap)Cl  
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Figure 13x: FTIR spectra of free ligand, Hap and mixed-ligand diruthenium complex, 
Ru2(OAc)3(ap)Cl. 
 
 
Figure 14x: Mass spectrum of Ru2(OAc)3(2-Meap)Cl. 
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Figure 15x: FTIR spectrum of free ligand, H(2-Meap) and mixed-ligand diruthenium 
complex, Ru2(OAc)3(2-Meap)Cl. 
 
 
 
 
 
 
 
 
 
 
